paclitaxel has been researched along with Epithelial Ovarian Cancer in 398 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.25) | 29.6817 |
| 2010's | 271 (68.09) | 24.3611 |
| 2020's | 126 (31.66) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, R; Bookman, MA; Coleman, RL; Fuh, KC; Herzog, TJ; Liu, JF; McIntyre, G; Monk, BJ; Moore, KN; Rangwala, R; Thaker, PH | 1 |
| Deng, M; Guan, X; Guo, L; Lu, R; Tang, X; Wang, Y; Xie, S; Zhang, J; Zheng, H; Zhou, L | 1 |
| De, A; Deo, AN; Dhadve, AC; Ray, P; Rekhi, B; Thorat, R | 1 |
| Chen, H; Cottu, PH; Davidson, TM; Fasching, PA; Feisel-Schwickardi, G; Glaspy, JA; Haluska, P; Hendrickson, AEW; Karlan, BY; Konecny, GE; Ma, S; Mahner, S; Mullany, SA; Poelcher, M; Provencher, DM; Ray-Coquard, IL; Rody, A; Roman, LD; Sehouli, J; Slamon, DJ; Winterhoff, BJ; Yachnin, A | 1 |
| Chang, WH; Lai, WA; Lee, NR; Lee, WL; Shen, SH; Wang, PH; Yang, ST | 1 |
| Dong, M; Feng, Y; He, J; Li, Q; Liang, M; Shi, S; Tian, YN; Yang, Y; Zhang, J | 1 |
| Condello, M; Gallo, FR; Meschini, S; Multari, G; Pellegrini, E; Vecchiotti, D; Zazzeroni, F | 1 |
| Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL | 1 |
| Aghajanian, C; Ansell, PJ; Birrer, MJ; Bookman, MA; Coleman, RL; Dinh, MH; Fleming, GF; Friedlander, M; Kaufmann, SH; Levine, DA; Moore, KN; O'Malley, DM; Okamoto, A; Reid, TJ; Sehgal, V; Shahin, MS; Spirtos, NM; Steffensen, KD; Swisher, EM | 1 |
| Aghajanian, C; Bookman, MA; Chan, JK; Coleman, RL; Dinh, MH; Fleming, GF; Friedlander, M; Hashiba, H; Moore, KN; O'Malley, DM; Okamoto, A; Ratajczak, C; Steffensen, KD; Swisher, EM; Tewari, KS; Wu, M | 1 |
| Chen, T; Chen, X; Cheng, W; Huang, Y; Jiang, Y; Nie, X; Zhong, Y | 1 |
| Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F | 1 |
| Beesley, VL; Campbell, R; DeFazio, A; Friedlander, ML; Grant, P; King, MT; Nagle, CM; Obermair, A; Ross, TL; Webb, PM | 1 |
| Li, N; Yang, L; Zuo, H | 1 |
| Bera, T; Chatterjee, P; Mahata, S; Mandal, S; Mistry, T; Nasare, VD; Pal, R; Sahoo, PK; Sarkar, S; Vernekar, M | 1 |
| Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Korolkiewicz, RP; Mallmann, P; Melichar, B; Minar, L; Novotny, Z; Pluta, M; Rob, L; Spacek, J; Spisek, R; Valha, P | 1 |
| Balusikova, K; Daniel, P; Ehrlichova, M; Holy, P; Hruda, M; Jelinek, M; Kloudova-Spalenkova, A; Koucka, K; Kovar, J; Mrhalova, M; Ojima, I; Rob, L; Seborova, K; Soucek, P; Vaclavikova, R; Voleska, I; Wang, C | 1 |
| Hwang, WY; Kim, JH; Kim, K; Kim, YB; Lee, M; No, JH; Suh, DH | 1 |
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Claes, N; De Maeseneer, D; De Waele, S; Debrock, G; Denys, H; Dirix, L; Gennigens, C; Graas, MP; Honhon, B; Lamot, C; Martinez Mena, C; Mebis, J; Pelgrims, G; Spoormans, I; Van den Bulck, H; van Gorp, T; Van Nieuwenhuysen, E; Van Steenberghe, M; Vergote, I; Verhoeven, D; Vroman, P; Vulsteke, C; Vuylsteke, P | 1 |
| Berger, J; Marth, C; Polterauer, S; Reinthaller, A; Schauer, C; Tsibulak, I | 1 |
| Fu, C; Yang, X | 1 |
| Clamp, A; Cook, A; Goh, BC; Goh, RM; Huang, RY; James, E; Ngoi, NY; Soon, YY; Syn, NL; Tan, DS | 1 |
| Cai, B; Dang, Y; Fu, Y; Li, Y; Lin, R; Liu, Q; Mao, B; Qiu, W; Tuo, S | 1 |
| Choi, CH; Joung, JG; Kim, BG; Kim, HS; Kim, JW; Kim, S; Lee, JB; Lee, JY; Park, E | 1 |
| Sugarbaker, PH | 1 |
| de la Rosa, CN; Fiorentino, F; Krell, J; Webber, L | 1 |
| Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H | 1 |
| Carulli, I; Chea, V; Cheng, SC; Curtis, J; Fasse, J; Frackiewicz, L; Huang, T; Keskin, DB; Konstantinopoulos, PA; Le, P; Li, S; Liu, JF; Liu, M; Livak, KJ; Matulonis, UA; Neuberg, D; Penter, L; Qi, C; Sellars, M; Stover, EH; Tarren, A; Tayob, N; Wu, CJ; Zhang, G | 1 |
| Chen, K; Ge, W; Lin, H; Lu, W; Shen, Y; Wu, Y; Xia, D | 1 |
| Borucka, J; Januchowski, R; Kaźmierczak, D; Klejewski, A; Nowacka, M; Nowicki, M; Ramlau, R; Sterzyńska, K; Świerczewska, M; Wojtowicz, K; Zabel, M | 1 |
| Ma, C | 1 |
| Allard, M; Bastida-Ruiz, D; Cohen, M; Dietrich, PY; Petignat, P; Yart, L | 1 |
| He, ZX; Hu, CB; Li, Q; Nie, L; Song, GB; Tan, J; Wen, F; Xu, CX; Yang, HL; Zhao, X; Zhou, SF; Zhou, ZW; Zi, D | 1 |
| Feng, Q; Quan, Q; Sheng, H; Sheng, X; Zhang, P | 1 |
| Fan, L; Han, Y; Wang, H; Wu, X | 1 |
| Götte, M; Győrffy, B; Kiesel, L; Parnigoni, A; Passi, A; Riecks, J; Vigetti, D | 1 |
| Guo, X; Jia, J; Liu, R; Miao, D; Pei, J; Shen, Y; Tang, H; Xie, Y; Zheng, Y; Zhu, M | 1 |
| Chen, G; Chen, JH; He, RQ; Huang, SN; Huang, ZG; Li, J; Liang, ZQ; Luo, JY; Shi, L; Wei, KL; Zeng, JH; Zeng, JJ; Zhong, LY | 1 |
| Cho, YJ; Choi, CH; Choi, JJ; Choi, JW; Lee, B; Lee, DH; Lee, EJ; Lee, JW; Lee, S; Lee, YY; Paik, ES | 1 |
| Bae, S; Hong, J; Jang, SK; Jin, HO; Kim, G; Kim, YJ; Lee, JH; Park, IC | 1 |
| Abadie-Lacourtoisie, S; Brachet, PE; D'Hondt, V; Del Piano, F; Falandry, C; Floquet, A; Frenel, JS; Freyer, G; Gladieff, L; Komulainen, M; Lorusso, D; Mollon-Grange, D; Mouret-Reynier, MA; Pommeret, F; Pujade-Lauraine, E; Rousseau, F; Stefani, L; Tinquaut, F; Trédan, O; Warkus, T | 1 |
| Chen, J; Chen, M; Huang, X; Liu, J; Shangguan, M; Wang, T; Wu, S; Yang, Z; Zhang, C; Zhao, S | 1 |
| Bell, JG; Casablanca, Y; Chan, JK; Copeland, LJ; Hanjani, P; Herzog, T; Kapp, DS; Kesterson, JP; Lentz, S; Lin, K; McNally, L; Monk, BJ; Richardson, MT; Robertson, S; Spirtos, NM; Tewari, KS; Tian, C; Walker, J; Wenham, RM | 1 |
| Bookman, MA; Burger, RA; Cappuccini, F; Cohn, D; Coleman, R; Colomban, O; Copeland, LJ; Fleming, G; Mannel, RS; Martin, L; Monk, BJ; Mutch, D; Muzaffar, M; Purdy, C; Randall, LM; Swisher, EM; Tewari, KS; Wahner-Hendrickson, A; Walker, JL; You, B | 1 |
| Baumann, K; Belau, A; Burges, A; Canzler, U; de Gregorio, N; Denschlag, D; El-Balat, A; Emons, G; Gropp-Meier, M; Hanker, LC; Harter, P; Hartkopf, AD; Hasenburg, A; Heubner, ML; Hilpert, F; Jackisch, C; Joly, F; Kristensen, G; Kurtz, JE; Lück, HJ; Mahner, S; Meier, W; Park-Simon, TW; Pautier, P; Pfisterer, J; Rau, J; Schmalfeldt, B; Schröder, W; Sehouli, J; Selle, F | 1 |
| Frountzas, M; Haidopoulos, D; Liatsou, E; Liontos, M; Papapanagiotou, A; Pergialiotis, V; Rodolakis, A; Thomakos, N | 1 |
| Tossetta, G | 1 |
| Chiba, N; Iida, Y; Iwamoto, M; Kiyokawa, T; Noguchi, D; Okamoto, A; Saito, M; Tabata, J; Takenaka, M; Yanagida, S; Yanaihara, N; Yoshino, Y | 1 |
| Bohart, RD; Goldstein, BH; Micha, JP; Rettenmaier, MA | 1 |
| Abadie-Lacourtoisie, S; Alexandre, J; Becourt, S; Berton, D; Bonichon-Lamichhane, N; Bouchaert, P; De Rauglaudre, G; Del Piano, F; Delanoy, N; Desauw, C; Dohollou, N; Dubot, C; Fabbro, M; Favier, L; Ferron, G; Floquet, A; Follana, P; Gantzer, J; Gouy, S; Joly, F; Kaminsky, MC; Leheurteur, M; Lortholary, A; Lotz, JP; Louvet, C; Malaurie, E; Meunier, J; Pujade-Lauraine, E; Rastkhah, M; Ray-Coquard, I; Venat-Bouvet, L; You, B | 1 |
| Armstrong, DK; Arranz, JA; Coleman, RL; Fujiwara, K; Gabra, H; Ghamande, SA; González-Martín, A; Hanna, R; Herzog, TJ; Jia, Y; Monk, BJ; Pignata, S; Ramsay, L; Rubio, MJ; Scambia, G; Sehouli, J; Slomovitz, B; Tewari, KS; Ushijima, K; Vergote, IB; Vulsteke, C; Weil, SC; Wenham, RM; Zamagni, C | 1 |
| Huang, B; Sun, R; Wei, LJ | 1 |
| Matsuda, Y; Okamoto, A; Yanaihara, N | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
| Chatelut, E; de Jong, LAW; de Vries, L; Lambert, M; Ottevanger, PB; van Erp, NP | 1 |
| Banerjee, S; Banerji, U; Cheng, Z; Clamp, AR; Ennis, DP; George, A; Giannone, G; Glasspool, RM; Gourley, C; Green, C; Herbertson, R; Hinsley, S; Krell, J; Kristeleit, RS; Lewsley, LA; McDermott, J; McNeish, IA; Mirza, HB; Rai, D; Riisnaes, R | 1 |
| Geng, A; Wang, Z; Wu, C; Yang, H | 1 |
| Arend, R; Barroilhet, LM; Birrer, M; Bradley, W; Castro, C; Dholakia, J; Duska, LR; ElNaggar, AC; Goodman, HM; Hamilton, E; Jackson, CG; Kagey, MH; Liu, A; LyBarger, K; Mahdi, H; Matulonis, U; O'Malley, DM; Piper, D; Sachdev, J; Sirard, CA | 1 |
| Clamp, A; Colomban, O; Cook, A; McNeish, IA; You, B | 1 |
| Bender, D; Bookman, MA; Chi, DS; Cohn, DE; Friedlander, M; Gershenson, DM; Gray, HJ; Lee, RB; Lichtman, SM; Lovecchio, JL; Menzin, AW; Mutch, DG; Purdy, C; Secord, AA; Sia, TY; Teoh, DG; Tew, WP; Tewari, KS; Van Le, L; Wahner Hendrickson, AE; Wenham, RM | 1 |
| Adams, KN; Ahmed, SJ; Akaputra, R; Akosman, I; Akya, A; Ali, S; Aminuddin, A; An, B; An, X; Anana, EV; Ao, L; Arany, Z; Arena, R; Azhar, A; Azhar, W; Baasankhuu, A; Bae, WK; Bahar, B; Balaji, L; Barbosa, M; Batchu, UR; Berg, KM; Berlin, N; Berthier, E; Bettiol, AA; Bi, B; Bodie, D; Borges, VF; Borghi-Silva, A; Bowman, CE; Brantly, M; Budhathoki, L; Bukhari, A; Cabeza, M; Cao, J; Cao, Q; Cao, S; Carrasco-Nuñes, N; Caruso, FR; Carvalho, C; Chakrabarty, D; Chandra Mondal, P; Chandran, V; Chang, P; Chase, M; Chauhan, AS; Chauhan, PS; Che, J; Cheemalamarri, C; Chen, D; Chen, H; Chen, J; Chen, Q; Chen, X; Chen, Z; Chetri, BK; Cho, SW; Choi, TI; Chung, HC; Cocchi, MN; Collins, LC; Colombo, N; Come, SE; Custodio, JM; Dai, TY; De La Garza Ramos, R; de Oliveira, CR; Dębczak, A; DeMuri, GP; Deng, J; Deng, K; Dhanani, LY; Diaz, S; Djaharuddin, I; Dong, G; Dong, Q; Donnino, MW; Dwiyanti, R; Elango, KP; Eleswarapu, A; Evans, EGB; Fachri, M; Fang, Y; Fantappiè, G; Farasat, A; Farsida, F; Fathimah, A; Febrianti, A; Feng, S; Fernandes, V; Fernandez Garcia, E; Fleming, GF; Foskett, JK; Fourman, MS; Fu, M; Fu, W; Fukushima, S; Gahlay, GK; Gai, S; Gao, R; Gao, W; Gilbert, DM; Gong, J; Gong, MN; Gong, Z; González-Cavieres, L; Gordon, SE; Goudarzi, F; Goulart, CDL; Greenstein, AE; Grigg, ARC; Grilli, D; Grisham, RN; Grossestreuer, AV; Grzęda, A; Grzegorczyk, A; Gu, J; Guo, H; Gupta, R; Haldar, A; Hamid, Y; Han, HJ; Hancock, CN; Hassan, GW; Hatta, M; He, D; He, F; He, J; Heidarinia, H; Helmchen, G; Herrera-Lavados, C; Hieber, DL; Hoehr, C; Hou, L; Huang, C; Huang, J; Hussain, S; Imaoka, S; Indoliya, Y; Jain, E; Jana, S; Jang, H; Jang, HS; Jara-Quijada, E; Jeacopello, I; Jeung, HC; Jiang, B; Jiang, D; Jiang, G; Jiang, L; Jiang, Q; Jiang, Y; Jiang, Z; Jiao, Z; Jr, JCB; Jung, M; Jung, S; Junita, AR; Kalavathi, A; Kang, X; Kannan, R; Kato, K; Khadka, M; Khan, AR; Khan, I; Khodayari, N; Kim, BJ; Kim, CG; Kim, CH; Kim, D; Kim, H; Kim, HS; Kim, HT; Kim, TS; Kim, YT; King, R; Koh, K; Konkol, M; Koo, DH; Kretzschmar, R; Krop, IE; Kuang, Y; Kubeneck, LJ; Kulkarni, K; Kumar, N; Kunjan, C; Kwon, WS; Lai, C; Lans, A; Lascano, J; Lavania, UC; Lee, CK; Lee, DA; Lee, HS; Lee, J; Lee, KH; Lee, MS; Lee, SW; Lee, UN; Lemus-Mondaca, R; Li, HR; Li, J; Li, Q; Li, X; Li, Y; Li, Z; Liang, H; Liang, Y; Lin, L; Lin, Y; Lipsyc-Sharf, M; Liu, B; Liu, C; Liu, DX; Liu, H; Liu, J; Liu, K; Liu, S; Liu, X; Liu, Z; Locknane, MP; Lorusso, D; Lü, H; Luo, Z; Lv, X; Ma, Y; Mandava, K; Manfrinetti, P; Mao, W; Marques-Sá, J; Masaki, T; Massi, MN; Matsuse, M; Matulonis, UA; Maxwell, CA; McAssey, EV; McManamen, AM; Mehl, RA; Mendes, RG; Meng, Z; Miao, Z; Miller, S; Milovanovic, S; Mishra, SK; Mitra, S; Mitsutake, N; Miyazaki, Y; Moriwaki, S; Mortenson, R; Moskowitz, A; Mudring, AV; Mues Genannt Koers, L; Muhammad, S; Muhimpundu, S; Murapaka, C; Murota, H; Mv, S; Nakazawa, Y; Nam, CM; Natzir, R; Ngo, L; Nguyen, DD; Nie, Y; Nishigori, C; Noji, MC; Notini, L; Oaknin, A; Ogi, T; Oguro, A; Okukawa, K; Olawaiye, AB; Omble, AD; Oso, T; Page, CA; Palma-Acevedo, A; Pani, M; Parikh, SM; Park, J; Park, S; Partridge, AH; Pashova, HI; Paudel, U; Paulssen, E; Payero, L; Peng, M; Peppercorn, JM; Pérez-Won, M; Pitarresi, JR; Pradhan, J; Prevost, D; Primaguna, MR; Puvvada, N; Qian, D; Rajaure, YS; Rajca, A; Rajput, N; Rana, SR; Rangan, L; Ranjbarian, P; Redd, PS; Ren, T; Rha, SY; Riley, L; Romano, M; Rong, X; Rosenberg, SM; Rostamian, M; Rothwell, KA; Ru, S; Ruddy, KJ; Rustgi, AK; Salam, A; Sankaran, S; Santoso, A; Saravanakumar, P; Satheeshkumar, K; Schapira, L; Schulz, K; Senapati, A; Senju, C; Sharma, P; Shelke, RG; Shen, F; Shen, X; Shen, Y; Sheteiwy, MS; Shetty, PR; Shi, L; Shi, MM; Shiigi, H; Shimada, M; Shinkawa, VAM; Shtender, V; Siswanto, FM; Smetana, V; Snow, C; Sridiana, E; Stephenson, MW; Stoll, S; Su, X; Sun, S; Sun, XF; Surapaneni, JR; Suri, K; Świątek, Ł; Syukri, A; Tabilo-Munizaga, G; Takezawa, MG; Tamimi, RM; Tamura, A; Tanaka, K; Tang, M; Tao, Y; Tateishi, S; Thapa, B; Theberge, AB; ThomasArrigo, LK; Thongpang, S; Tiwari, M; Tong, Q; Totton, RR; Tripathi, RD; Tsujimoto, M; Tu, WC; Tudor, IC; Tyskiewicz, K; Ubaidah, FM; Ulhassan, Z; Utani, A; Van Gorp, T; Veerapandian, V; Vennila, KN; von Gunten, U; Wagle, N; Waks, AG; Wald, ER; Wang, B; Wang, D; Wang, H; Wang, L; Wang, W; Wang, X; Wang, Y; Wang, Z; Warner, E; Waterhouse, GIN; Weiss, J; Weissenrieder, JS; Wellen, KE; Wu, JY; Xiang, W; Xiao, S; Xie, Q; Xu, F; Xu, TW; Xu, Y; Yan, B; Yan, JM; Yang, D; Yang, P; Yang, S; Yang, W; Yao, Y; Yassari, R; Yong, Q; Yu, H; Yu, Z; Yun, UJ; Zagotta, WN; Zang, DY; Zanudo, JGT; Zeng, A; Zhang, H; Zhang, R; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YT; Zhao, C; Zhao, J; Zhong, S; Zhou, F; Zhou, W; Zhou, Y | 1 |
| Choi, KU; Kim, D; Kim, DK; Kim, JH; Kim, JS; Lee, SY; Shin, MJ; Suh, DS | 1 |
| Cao, C; Fang, Y; Gao, Q; Gong, W; Yu, R; Zhao, X | 1 |
| Abe, R; Kawamura, N; Kawanishi, M; Murakami, M; Nagatsuji, M; Okajima, S; Suruga, M; Tokuyama, O; Yamane, T | 1 |
| Chen, D; Chen, H; Tan, X; Zou, S | 1 |
| Maowulieti, G; Yuan, H; Zhao, M; Zhao, S | 1 |
| Dawson, MR; Ghosh, D; Hsu, J; Mejia Peña, C; Schechter, I; Skipper, TA | 1 |
| Cibula, D; Colombo, N; de Gregorio, N; Gaba Garcia, L; Gropp-Meier, M; Hahnen, E; Harter, P; Hasenburg, A; Hauke, J; Heitz, F; Henry, S; Marth, C; Polleis, S; Reuss, A; Schmalfeld, B; Schouten, PC; Sehouli, J; Wimberger, P | 1 |
| Kinnel, B; McFadden, M; Singh, R; Singh, SK; Varambally, S | 1 |
| Chang, WH; Chou, FW; Lee, WL; Liu, HH; Wang, PH; Yang, ST | 1 |
| Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I | 1 |
| Chen, Y; Fu, Z; Wang, C; Wang, X; Xie, X; Zhang, X | 1 |
| Ikeda, Y; Kajiyama, H; Kikkawa, F; Niimi, K; Nishino, K; Sakata, J; Shimbo, A; Suzuki, S; Tamauchi, S; Yoshikawa, N | 1 |
| Gao, SP; Huang, W; Li, KS; Luo, JH; Wang, F; Wu, J; Wu, Y; Zhang, PF; Zhang, PN; Zhang, XM | 1 |
| Liu, Y; Sun, H; Zhang, H; Zheng, Y; Zhu, J | 1 |
| Jimi, T; Kaneda, M; Kitai, M; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Sudo, T; Suzuki, K; Yamaguchi, S; Yamamoto, K; Yano, H | 1 |
| Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gordon, S; Gray, HJ; Guntupalli, SR; Hagemann, AR; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, RE; O'Malley, D; Schilder, RJ; Walker, JL | 1 |
| Chen, Y; He, J; Li, ZL; Li, ZM; Pan, XH; Shi, XY; Xiao, L; Yan, SJ | 1 |
| Li, H; Pi, R; Qian, Y; Wang, X; Wei, X; Zhao, X | 1 |
| Kaneuchi, M; Kobayashi, Y; Machida, H; Matsumura, N; Matsuo, K; Mikami, M; Nagase, S; Tabata, T; Tokunaga, H | 1 |
| Angioli, R; Bayever, E; Braly, P; Brewer, M; Ferrandina, G; Holloway, R; Lorusso, D; Madiyalakan, M; Method, M; Nicodemus, C; Panici, PB; Plotti, F; Raspagliesi, F; Ricci, C; Salutari, V; Scambia, G; Scollo, P; Terranova, C | 1 |
| Alvarez Secord, A; Bakkum-Gamez, JN; Bell Burdett, K; Birrer, MJ; Boente, M; Brady, JC; Burger, RA; Deng, W; Fujiwara, K; Gray, H; Hurwitz, HI; Lankes, HA; Liu, Y; Mannel, RS; Nixon, AB; O'Malley, DM; Owzar, K; Sibley, AB; Starr, MD; Tewari, KS; Tritchler, D | 1 |
| Bizzarri, N; D'Indinosante, M; Fagotti, A; Garganese, G; Ghirardi, V; Loverro, M; Moruzzi, MC; Pasciuto, T; Scambia, G; Vargiu, V | 1 |
| Deng, Z; Gao, L; He, X; Huang, X; Li, J; Lin, S; Liu, N; Ou, L; Song, Y; Wang, X | 1 |
| Burger, R; Coleman, RL; Handley, KF; Molin, GZD; Moore, KN; Sood, AK; Stagg, R | 1 |
| Adorni, M; Cosio, S; Ferrero, AM; Gadducci, A; Landoni, F; Lissoni, AA; Sartori, E; Zizioli, V | 1 |
| Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Broekman, KE; Gietema, JA; Hof, MAJ; Jalving, M; Lefrandt, JD; Nijman, HW; Reyners, AKL; Touw, DJ | 1 |
| Aleohin, N; Elyashiv, O; Levy, T; Migdan, Z; Peled, O; Tal, O | 1 |
| Chen, Y; Feng, L; Jiang, R; Li, Y; Shen, F; Zhou, J | 1 |
| Choi, DK; Kim, DK; Kim, JH; Kim, JW; Kwon, OB; Lee, DS; Lee, H; Lee, J; Lee, S; Min, SH; Yu, JH | 1 |
| Eoh, KJ; Kim, S; Kim, SW; Kim, YT; Lee, JY; Nam, EJ; Park, J | 1 |
| Carey, DJ; Dasari, VR; Gogoi, R | 1 |
| Chang, SJ; Ji, YI; Kim, HS; Kim, JW; Kim, SY; Kwon, SH; Lee, EJ; Lee, M; Lee, SH; Lee, SJ; Park, S; Park, SJ; Roh, JW; Shim, SH; Song, T | 1 |
| Chang, CM; Huang, CY; Wang, PH | 1 |
| Clevers, H; Cuppen, E; de Witte, CJ; Espejo Valle-Inclan, J; Hami, N; Jonges, GN; Kloosterman, WP; Kopper, O; Lõhmussaar, K; Nguyen, L; Snippert, HJG; Stelloo, E; van Diest, P; Vreuls, CPH; Witteveen, PO; Zweemer, RP | 1 |
| Chen, P; Feng, XN; He, H; Su, CH; Sun, LD; Zhao, DX; Zhao, YY | 1 |
| Chambers, L; Chichura, A; Costales, AB; Debernardo, R; Mahdi, H; Michener, CM; Rose, PG; Yao, M | 1 |
| Beke, L; Méhes, G; Molnár, S; Póka, R | 1 |
| Burges, A; Cron, N; Degregorio, N; Harter, P; Heitz, F; Kurzeder, C; Ledermann, J; Lindemann, K; Lorusso, D; Marme, F; Paoletti, X; Pautier, P; Petru, E; Redondo, A; Reuss, A; Sehouli, J; Van Nieuwenhuysen, E; Wimberger, P | 1 |
| Brand, A; van Dam, P; Vermorken, JB | 1 |
| Baldassarre, G; Belletti, B; Coan, M; D'Andrea, S; Dall'Acqua, A; Lorenzon, I; Lovisa, S; Pellarin, I; Polesel, J; Ranzuglia, V; Sabatelli, P; Schiappacassi, M; Segatto, I; Serraino, D; Sonego, M; Spessotto, P | 1 |
| Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H | 1 |
| Asaturova, AV; Atkarskaya, MV; Brenner, PK; Burdennyi, AM; Kapralova, MA; Khabas, GN; Khodyrev, DS; Khokhlova, SV; Loginov, VI; Nosova, YA; Stenina, MB; Sukhikh, GT; Tyulyandina, AS; Zavarykina, TM | 1 |
| Bruce, JP; Cescon, DW; Chen, E; Clarke, B; Dhani, NC; Garg, S; Lee, YC; Lheureux, S; Madariaga, A; Mandilaras, V; Oza, AM; Rath, P; Thiryayi, S; Wang, L | 1 |
| Acar, H; Baghdasaryan, O; Gunay, G; Hamsici, S; Kamatar, A; Kirit, HA | 1 |
| Hashimoto, K; Ishida, K; Kimura, T; Kobayashi, M; Kodama, M; Miyamoto, M; Nakamura, K; Sawada, K; Shimizu, A; Yamamoto, M; Yoshimura, A | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Chambers, LM; Chichura, A; Costales, AB; Debernardo, R; Gruner, M; Horowitz, MP; Michener, C; Morton, M; Rose, PG; Yao, M | 1 |
| Muggia, F | 1 |
| Cao, J; Dai, C; Fu, Z; Jia, X; Liu, G; Liu, S; Lv, M; Xu, J; Xu, P; Xu, S; Zhang, H; Zhou, J | 1 |
| Pei, ML; Shuang, T; Zhao, ZX | 1 |
| Derchain, S; Ferracini, AC; Kroetz, DL; Lima, CSP; Lopes-Aguiar, L; Lourenço, GJ; Mazzola, PG; Sarian, LO; Yoshida, A | 1 |
| Dong, S; Guo, X; Huang, L; Lu, G; Qin, W; Wang, Z; Zhai, Z; Zhang, C | 1 |
| Fariñas, L; Grau, F; Oaknin, A; Perez-Fidalgo, JA | 1 |
| Cao, J; Li, Y; Liu, Y; Long, T; Luo, J; Luo, Y; Qiao, B; Sun, Y; Wang, ZG; Yang, Q; Yang, Z; Yuan, D; Zhang, N | 1 |
| Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gillen, J; Gordon, SW; Gray, HJ; Guntupalli, SR; Hagemann, AR; Hays, J; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, R; Schilder, RJ; Walker, JL | 1 |
| Brown, R; Chiu, DS; Choi, H; Hoppe, MM; Huntsman, DG; Jaynes, P; Jeyasekharan, AD; Karnezis, A; Kaye, SB; Leung, S; Lie, S; Lim, DGZ; Lim, S; P S Yeong, J; Pang, BNK; Patel, NR; Pitt, JJ; Sato, K; Scott, CL; Sedukhina, AS; Tan, DSP; Tan, TZ; Topp, MD; Upadhyayula, SS; Wardyn, JD | 1 |
| An, R; Li, M; Ma, Y; Yang, Y; Zhang, S | 1 |
| Bourbouloux, E; Brachet, PE; D'Hondt, V; Falandry, C; Freyer, G; Herrstedt, J; Lortholary, A; Lorusso, D; Malaurie, E; Mouret-Reynier, MA; Mourey, L; Pujade-Lauraine, E; Rousseau, F; Savoye, AM; Stefani, L; Sverdlin, R; Tinquaut, F; Trédan, O; Venat-Bouvet, L; Zannetti, A | 1 |
| Aghajanian, C; Anderson, C; Bookman, M; Colombo, N; Darus, CJ; Garcia, Y; Gold, MA; Khor, VK; Lin, YG; Liontos, M; Mäenpää, J; Maiya, V; Miller, A; Molinero, L; Moore, KN; Myers, T; Okamoto, A; Pignata, S; Robison, K; Safin, R; Scambia, G; Sehouli, J; Sharma, SK; Taskiran, C; Thomes-Pepin, J; Willmott, L; Wu, F; Wu, X | 1 |
| Arenare, L; Artioli, G; Bogani, G; Breda, E; Cecere, SC; Cinieri, S; Colombo, N; Daniele, G; De Censi, A; De Giorgi, U; Distefano, M; Ferrero, A; Fossati, R; Frezzini, S; Gadducci, A; Gallo, C; Giannone, G; Greggi, S; Katsaros, D; Lauria, R; Lissoni, AA; Lorusso, D; Nardin, M; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Salutari, V; Scambia, G; Scollo, P; Tognon, G; Zaccarelli, E | 1 |
| Ahmed, AA; Albukhari, A; Alsaadi, A; Artibani, M; Bast, RC; Blagden, SP; Campo, L; Chong, K; Damato, S; Dhar, S; Ejsing, CS; El-Sahhar, S; Gleeson, F; Harris, AL; Hu, Z; KaramiNejadRanjbar, M; Klemm, RW; Laios, A; Lu, Z; Mallett, G; Masuda, K; Morotti, M; Motohara, T; Nicum, S; Pathiraja, PN; Rauher, PC; Santana Gonzalez, L; Sauka-Spengler, T; Wietek, N; Yau, C; Zois, CE | 1 |
| Bryce, NS; Ford, CE; Friedlander, M; Gunning, PW; Hardeman, EC; Kang, EY; Kelemen, LE; Köbel, M; Meagher, NS; Ramus, SJ; Tang, K; Wang, Y; Xu, X | 1 |
| Chang, TC; Chang, WY; Chao, A; Chen, MY; Chen, WC; Chou, HH; Huang, HJ; Huang, KG; Lai, CH; Lin, H; Qiu, JT; Wu, RC; Yang, LY | 1 |
| Aghajanian, C; Bookman, MA; Coleman, RL; Fleming, GF; Friedlander, M; Jackson, CG; Okamoto, A; Ratajczak, CK; Steffensen, KD; Sullivan, D; Swisher, EM | 1 |
| Guo, YN; Leng, YL; Liu, HX; Tang, JL; Wang, XY; Yang, TT; Yu, JY; Zhang, LY; Zhang, XC; Zhu, RR | 1 |
| Backes, FJ; Bixel, K; Chen, M; Cohn, DE; Copeland, LJ; Cosgrove, C; Dzwigalski, K; Fowler, JM; Hays, J; Hill, K; O'Malley, D; Phelps, M; Poi, M; Salani, R; Wei, L | 1 |
| Cui, D; Dong, XD; Huang, S; Lai, HY; Li, M; Lyu, QB; Yang, CX; Zhang, W | 1 |
| Azevedo, RB; Bonadio, RS; de Lima, LI; de Matos Neto, JN; de Oliveira, MC; Faria, RS; Longo, JPF; Moya, SE; Roque, MC | 1 |
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Balega, J; Elattar, A; Kehoe, S; Nevin, J; Phillips, A; Singh, K; Sundar, S | 1 |
| Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Birrer, M; Brozick, J; Bshara, W; Edwards, RP; Grabosch, S; Lankes, HA; Lugade, A; Ma, T; Moore, K; Odunsi, K; Omilian, A; Strange, M; Stuckey, AR; Tseng, G; Vlad, A; Walker, JL | 1 |
| Bergzoll, C; Eva, L; Jamieson, A; Simcock, B; Sykes, P | 1 |
| Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A | 1 |
| Alberts, DS; Angioli, R; Baldelli, E; Dong, T; Gambara, G; Guillen-Rodriguez, JM; Hodge, KA; Liotta, LA; Memo, M; Odicino, F; Pecorelli, SL; Petricoin, EF; Pierobon, M; Ravaggi, A; Sereni, MI | 1 |
| Boban, T; Boraska Jelavić, T; Brčić, L; Vrdoljak, E | 1 |
| Chen, Y; Teng, NNH; Westhoff, GL | 1 |
| Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Chung, JY; Hewitt, SM; Jeon, HK; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Ryu, JY; Ylaya, K | 1 |
| Curry, E; Gabra, H; Janczar, S; Nautiyal, J; Paige, AJ; Sun, M; Xiao, Y; Zanini, E | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Jia, L; Jin, H; Lu, Y; Lv, M; Ming, Y; Yu, Y; Zhao, H; Zhao, N; Zheng, Z; Zhou, J | 1 |
| Copeland, NG; Hanash, SM; Hashimoto, K; Jenkins, NA; Katayama, H; Kimura, T; Kobayashi, M; Kodama, M; Kodama, T; Mabuchi, S; Newberg, JY; Rangel, R; Sawada, K; Tien, JC; Wei, Z; Yoshihara, K | 1 |
| Chen, WT; Dombroff, MK; Dong, H; Pearl, ML; Tulley, S; Zhao, Q | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M | 1 |
| Armstrong, DK; Bessette, P; Brundage, M; Eisenhauer, EA; Feeney, M; Fung-Kee-Fung, M; Gallagher, CJ; Gauthier, P; Gonzalez-Martin, A; Gourley, C; Hall, G; Hall, M; Lau, SK; Ledermann, JA; MacKay, HJ; Parulekar, WR; Provencher, DM; Romero, I; Tu, D; Weberpals, JI; Winch, C | 1 |
| Auguste, A; Genestie, C; Khairallah, AS; Leary, A | 1 |
| Marth, C; Reimer, D; Zeimet, AG | 1 |
| Chan, JK; Monk, BJ | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| Guo, Q; Huang, S; Li, Z; Liao, Y; Liu, Y; Lu, L; Sun, H; Wang, X; Zhang, Y; Zhao, L | 1 |
| Aalbers, AGJ; Aaronson, NK; Arts, HJ; de Hingh, IHJT; Hermans, RHM; Kieffer, JM; Koole, SN; Massuger, LFAG; Schagen van Leeuwen, JH; Schreuder, HWR; Sikorska, K; Sonke, GS; Van de Vijver, KK; van der Velden, J; van Driel, WJ; van Tinteren, H; Verwaal, VJ | 1 |
| Balleine, RL; Beale, P; Beesley, J; Boere, I; Chenevix-Trench, G; Chiew, YE; Conroy, D; de Bruijn, P; de Fazio, A; de Graan, AM; Gao, B; Gurney, H; Harrison, M; J Kennedy, C; Johnatty, SE; Lu, Y; Luccarini, C; Macgregor, S; Mathijssen, RHJ; Nieuweboer, AJM; R Harnett, P; Xu, H | 1 |
| Ayhan, A; Celik, H; Coban, G; Cuylan, ZF; Güngör, T; Haberal, AN; Meydanli, MM; Sahin, H; Sari, ME; Sirvan, L; Yalcin, I | 1 |
| Stirrups, R | 1 |
| Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G | 1 |
| Bristow, RE; Burger, RA; Eskander, RN; Fujiwara, K; Glaser, GE; Hamilton, CA; Huh, WK; Kauderer, J; Mannel, RS; O'Malley, DM; Rubin, SC; Stephan, JM; Tewari, KS; Ueland, F | 1 |
| Mandai, M; Matsumura, N; Murakami, K; Nakai, H; Suzuki, A; Takaya, H; Tobiume, T | 1 |
| Dos Santos Guimarães, I; Dos Santos, DZ; Gimba, ERP; Ladislau-Magescky, T; Rangel, LBA; Silva, IV; Sternberg, C; Tessarollo, NG | 1 |
| Akbayir, O; Ayhan, A; Celik, H; Cuylan, ZF; Dede, M; Gungor, T; Gungorduk, K; Kuscu, E; Meydanli, MM; Ozgul, N; Sahin, H; Sari, ME | 1 |
| Agarwal, R; Chawla, D; Garg, S; Gupta, B; Halder, S; Kar, R; Mehndiratta, M; Wadhwa, N | 1 |
| Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Chen, H; Dong, W; Hou, Y; Li, B; Lin, M; Lou, G; Xia, B; Zhang, X | 1 |
| Zhang, L; Zhou, Q | 1 |
| Ahn, HJ; Byeon, Y; Cho, YJ; Choi, WS; Han, HD; Jung, ID; Kang, TH; Kim, GH; Kim, MG; Lee, JM; Lee, JW; Lee, YJ; Park, YM; Shin, BC; Sood, AK; Wi, TI; Won, JE | 1 |
| Bodurka, DC; Bookman, MA; Friedlander, M; Geller, M; Glaser, G; Herzog, TJ; Java, JJ; Krivak, TC; Lee, RB; Mutch, DG; O'Malley, DM; Olawaiye, AB; Wenham, RM | 1 |
| Ghaem-Maghami, S; Jung, Y; Lam, EW; Maher, J; Natoli, M; Parente-Pereira, AC; Smith, JR; Wahba, J; Whilding, LM; Zona, S | 1 |
| Beck, HM; Fuh, KC; Guo, L; Hagemann, AR; Ilivicky, AR; Lawrence, JA; Lomonosova, E; McCourt, C; Mills, KA; Mutch, DG; Powell, MA; Quinn, JM; Roach, ST; Starks, CM; Thaker, PH | 1 |
| Hirasawa, T; Iida, T; Ikeda, M; Machida, H; Mikami, M; Shida, M | 1 |
| Komiyama, S; Kubushiro, K; Kugimiya, T | 1 |
| Lee, MX; Tan, DS | 1 |
| Barra, F; Casarin, J; Ferrero, S; Ghezzi, F; Laganà, AS | 1 |
| Chen, M; Lu, X; Shao, G; Shao, Q; Shen, R; Wan, B; Wang, H; Wu, C; Xia, S; Yan, M; Yang, P; Yang, X; Ye, Q; Yu, J; Zhang, L; Zhang, Q; Zhou, X | 1 |
| Alexandre, J; Åvall-Lundqvist, E; Canzler, U; Colombo, N; Cormio, G; du Bois, A; Fiane, B; Hanker, LC; Harter, P; Heitz, F; Herrstedt, J; Leminen, A; Merger, M; Ottevanger, PB; Pautier, P; Poveda, A; Reinthaller, A; Reuss, A; Sehouli, J; Vergote, I | 1 |
| Shi, C; Wang, M | 1 |
| Aghajanian, C; Bender, DP; Carlson, JW; Crane, EK; Darus, CJ; Makker, V; Mannel, RS; Matulonis, UA; Mutch, DG; Sill, MW | 1 |
| Kim, JC; Kim, JH; Kim, YM; Yoon, YS | 1 |
| Gadducci, A; Guarneri, V; Peccatori, FA; Ronzino, G; Salutari, V; Scandurra, G; Zamagni, C; Zola, P | 1 |
| Huang, Y; Liu, M; Shi, Y; Yin, L; Zhang, J | 1 |
| de la Motte Rouge, T; Ray-Coquard, I; You, B | 1 |
| Bakrin, N; Gladieff, L | 1 |
| Akilli, H; Altundag, O; Ayhan, A; Karakas, LA; Rahatli, S; Tohma, YA | 1 |
| Armstrong, DK; Birrer, MJ; Castro, C; Dizon, DS; Drescher, C; Krasner, CN; Lee, H; Matulonis, UA; Morgan, MA; Penson, RT; Roche, M; Seiden, M; Supko, JG; Wolfe, JK | 1 |
| Calzas, J; Carrión, L; Manzanedo, I; Martínez-Torres, B; Pereira, F; Pérez-Viejo, E; Serrano, Á | 1 |
| Bajić, Ž; Boban, T; Boraska Jelavić, T; Petrić Miše, B; Tomić, S; Vrdoljak, E; Vrdoljak, J | 1 |
| Li, L; Sun, T | 1 |
| Cybulski, M; Guz, M; Jeleniewicz, W; Kotarski, J; Marzec-Kotarska, B; Nowakowski, A; Stenzel-Bembenek, A; Stepulak, A | 1 |
| Igarashi, A; Imada, H; Saitou, Y; Suzuki, K; Takakura, S | 1 |
| Chen, CC; Chou, CY; Huang, YF; Wu, YH | 1 |
| Brady, WE; Christensen, H; Dark, G; Feeney, A; Frumovitz, M; Ganesan, R; Gershenson, DM; Gore, M; Hackshaw, A; Kehoe, S; Ledermann, J; Lord, R; Mackean, M; McCluggage, WG; Montes, A; Penson, RT; Perren, T; Reed, N; Rustin, G; Summers, J; Wilkinson, N; Zaino, R | 1 |
| Arvanitis, C; Chen, L; Condello, S; Grigorescu, AA; Matei, D; Nwani, NG; Schiltz, GE; Sima, LE; Yakubov, B; Zhang, S; Zhang, ZY | 1 |
| Bamias, A; Colombo, N; Covens, A; Del Campo, JM; Kroep, JR; Ma, H; Marth, C; Meier, W; Monk, BJ; O'Malley, DM; Park, SY; Pickett, CA; Raza Mirza, M; Scambia, G; Van Calster, B; Vergote, I; Wenham, RM | 1 |
| Chigurupati, S; Hasan, MN; Islam, MJ; Kabir, S; Pervin, S; Roshid, B | 1 |
| Brachmann, RK; Burger, RA; Farooki, A; Gunderson, CC; Kapoun, AM; Mantia-Smaldone, G; McMeekin, DS; Moore, KN; Morgan, MA; O'Cearbhaill, RE; Sabbatini, P; Stagg, R | 1 |
| Blaakaer, J; Christiansen, T; Iversen, LH; Mikkelsen, MS; Petersen, LK | 1 |
| Bi, L; Gong, L; Li, P; Li, R; Wang, J | 1 |
| Amiji, MM; Gandham, SK; Leslie, F; Parayath, NN | 1 |
| Alldredge, J; Brooks, RA; Cass, I; Cohen, JG; Datta, A; Diaz Moore, ES; Hurteau, JA; Kim, JS; Kirschner, CV; Liang, MI; Penner, KR; Prendergast, EN; Rodriguez, G; Vogel, TJ; Wang, CE | 1 |
| Arevalo, JMG; Chisholm, GB; Cole, SW; Coleman, RL; Dizon, T; Fleming, N; Hu, W; Nick, AM; Ramirez, PT; Ramondetta, LM; Sahai, SK; Sood, AK; Sun, Y; Thaker, PH; Urbauer, DL; Westin, SN | 1 |
| Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y | 1 |
| DeFazio, A; Francis, J; Friedlander, M; Goss, G; Jordan, S; O'Brien, S; Obermair, A; Quinn, M; Steer, C; Webb, P; Wyld, D | 1 |
| Castro, C; de León, DC; Gallardo, D; Herrera, LA; López, A; Mendoza, J; Mohar, A; Morales, F; Oñate, LF; Perez, D; Prada, D; Santibáñez, M | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Hoffman, RM; Jung, PS; Kim, DY; Kim, JH; Kim, MB; Kim, YM; Kim, YT; Lee, SW; Nam, JH | 1 |
| Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM | 1 |
| Adank, MA; Burger, CW; de Bock, GH; de Hullu, JA; Gaarenstroom, KN; Kriege, M; Mourits, MJ; Reitsma, W; Rijcken, F; Schmidt, MK; Seynaeve, C; Slangen, BF; van Altena, AM; van Beurden, M; Vasen, HF; Vencken, PM; Zweemer, RP | 1 |
| Armstrong, DK; Copeland, LJ; Java, J; Landrum, LM; Lanneau, GS; Mathews, CA; Walker, JL | 1 |
| Hu, P; Kang, S; Li, Y; Sun, HY; Wang, N; Zhou, RM | 1 |
| Bodnar, L; Grala, B; Kozlowski, W; Smoter, M; Stec, R; Szczylik, C; Zieniuk, K | 1 |
| Chen, KJ; Chen, L; Chen, WY; Chen, X; Jia, YM; Peng, GQ | 1 |
| Alder, H; Baldassarre, G; Belletti, B; Califano, D; Canzonieri, V; Chiappetta, G; Cirombella, R; Croce, CM; Giglio, S; Losito, S; Lovat, F; Onesti, EC; Pellegrini, P; Pignata, S; Sonego, M; Sorio, R; Stoppacciaro, A; Vecchione, A; Volinia, S; Wernicke, D | 1 |
| Markman, M | 1 |
| Dhillon, S | 1 |
| Greenberg, J; Grisaru, D; Inbar, M; Levy, T; Matcejevsky, D; Pelles, S; Safra, T; Shamai, S; Shpigel, S; Veizman, A | 1 |
| Graeser, MK; Jaenicke, F; Mahner, S; Mathey, S; Milde-Langosch, K; Müller, V; Trillsch, F; Woelber, L; Zu Eulenburg, C | 1 |
| Li, D; Yao, X; Zhang, P | 1 |
| Kubushiro, K; Kurasaki, A; Sakurai, N; Takahashi, K; Taoka, H; Yamamoto, Y | 1 |
| Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA | 1 |
| Bean, Y; Beckmann, MW; Beesley, J; Berchuck, A; Brown, R; Camey, ME; Chen, X; Chenevix-Trench, G; Cramer, DW; Cunningham, JM; deFazio, A; Despierre, E; du Bois, A; Ekici, AB; Emmanuel, C; Fasching, PA; Fereday, S; Fridley, BL; Gao, B; Goode, EL; Goodman, MT; Haber, M; Harter, P; Hedditch, EL; Heitz, F; Henderson, MJ; Hogdall, C; Hogdall, E; Jensen, A; Johnatty, SE; Karlan, BY; Kjaer, SK; Lambrechts, S; Law, MH; Lester, J; Levine, DA; Lu, Y; Lurie, G; MacGregor, S; Norris, MD; Paul, J; Pejovic, T; Russell, AJ; Schwaab, I; Shildkraut, J; Terry, KL; Thompson, PJ; Vergote, I; Vierkant, RA; Webb, PM | 1 |
| Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M | 1 |
| Kruitwagen, RF; Massuger, LF; Ottevanger, PB; van de Laar, R; Van Gorp, T; Zusterzeel, PL | 1 |
| Crivellaro, C; Cuzzocrea, M; Dell'Anna, T; Dolci, C; Fruscio, R; Guerra, L; Messa, C; Milani, R; Signorelli, M; Sina, F | 1 |
| Barker, J; Burrell, M; Feuer, GA; Lakhi, N; Salmieri, S | 1 |
| Leary, A; Lhomme, C; Pautier, P; Tazi, Y | 1 |
| Fujiwara, K; Iwasaki, S; Muraji, M; Nishimura, R; Sudo, T; Ueno, S; Wakahashi, S; Yamaguchi, S | 1 |
| Lawrie, TA; Morrison, J; Rabbie, R; Thoma, C | 1 |
| Ahmed, N; Fraser, FW; Kumar, J; McCulloch, DR; Riley, C; Ward, AC | 1 |
| Walker, JL | 1 |
| Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V | 1 |
| da Costa Miranda, V; da Silva Bessa, LR; da Silva, JR; de Freitas, D; de Paula Carvalho, J; de Souza Fêde, ÂB; Del Pilar Estevez Diz, M; Dos Anjos, CH; Filho, EA; Sanchez, FB | 1 |
| Alvero, AB; Azodi, M; Craveiro, V; Gill, SK; Griffin, B; Holmberg, JC; Joo, WD; Mor, G; Pizzonia, J; Rutherford, T; Silasi, DA; Sumi, NJ; Yang-Hartwich, Y | 1 |
| Hong, JH; Jin, HM; Kim, JW; Lee, JK; Lee, NW; So, KA; Song, JY | 1 |
| Cheng, J; Deng, BF; Huang, JM; Lin, Q; Lu, HY; Ma, SQ; Shi, Y; Wang, MM; Wang, W; Zha, X; Zhang, GN; Zhu, Y | 1 |
| Hay, JW; Mehta, DA | 1 |
| González Ruiz de la Herrán, F; Haya Palazuelo, J; López de la Manzanara Cano, C; Martín Fernández, J; Padilla Valverde, D; Pascual-Ramírez, J; Sánchez García, S; Villarejo Campos, P | 1 |
| Brower, SL; Krivak, TC; Leath, CA; Lele, S; Moore, RG; Richard, S; Secord, AA; Tian, C | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Bodnar, L; Grala, B; Jakobsen, A; Smoter, M; Stec, R; Steffensen, KD; Szczylik, C; Waldstrøm, M | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Aoki, Y; Asakura, H; Doi, D; Fujita, K; Honma, S; Kamoi, S; Kato, H; Kodama, S; Konishi, H; Matsushima, T; Nakayama, H; Takeshita, T; Tanaka, K; Yahata, T; Yoneyama, K | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Cai, M; Gao, J; Hu, Z; Lin, B; Liu, C; Liu, D; Liu, J; Tan, M; Zhang, D | 1 |
| Benbrook, DM; Ding, K; McMeekin, DS; Moore, KN; Nelson, T; Penaroza, S; Slaughter, KN; Thai, T; Thavathiru, E | 1 |
| Blansit, K; Chan, JK; Herzog, TJ; Hu, L; Kapp, DS; Kiet, T; Monk, BJ; Yu, X | 1 |
| Chang, CL; Chen, CP; Cheng, JT; Lee, WL; Seow, KM; Tsui, KH; Wang, PH; Wang, SY; Yang, LW; Yen, MS | 1 |
| Ansaloni, L; Bogani, G; Coccolini, F; Frigerio, L; Grosso, G; Rossetti, D | 1 |
| Bratos, R; Chiva, L; González-Martín, A; Márquez, R; Sánchez-Lorenzo, L | 1 |
| Bae, DS; Bamias, A; Brize, A; Coleman, RL; Fabbro, M; Fujiwara, K; Herzog, TJ; Karlan, BY; Lhommé, C; Marth, C; Monk, BJ; Navale, L; Oaknin, A; Oza, AM; Poveda, A; Provencher, DM; Raspagliesi, F; Ray-Coquard, I; Redondo, A; Richardson, G; Rincón, DG; Tassoudji, M; Vergote, I; Warner, DJ | 1 |
| Ercoli, A; Fagotti, A; Margariti, PA; Pedone Anchora, L; Petrillo, M; Salutari, V; Scambia, G; Tortorella, L; Zannoni, GF | 1 |
| Barry-O'Crowley, J; Bates, M; Cooke, AA; Costello, KM; d'Adhemar, CJ; D'Arcy, T; Ffrench, B; Finn, S; Flood, B; Gallagher, MF; Gleeson, N; Haley, K; Hennessy, B; Kernan, N; Martin, CM; McCann, A; Murphy, C; O'Byrne, K; O'Donnell, D; O'Leary, JJ; O'Neill, LA; O'Toole, S; Pennington, S; Sheils, O; Smyth, PC; Spillane, CD; Stordal, B | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Braicu, EI; Darb-Esfahani, S; Denkert, C; Fotopoulou, C; Joens, T; Lindhofer, H; Mahner, S; Mellstedt, H; Pietzner, K; Richter, R; Sehouli, J; Woopen, H | 1 |
| Shen, K; Song, Y; Xia, Z; Xin, X; Zhai, X | 1 |
| Hewidy, M; Shawky, H; Tawfik, H | 1 |
| Byun, HJ; Kim, BR; Lee, SH; Rho, SB; Seo, SH; Yoon, K | 1 |
| Chaudhury, S; Gaikwad, SM; Jinager, A; Maheshwari, A; Ray, P; Singh, RK | 1 |
| Geller, M; Ramakrishnan, S; Rivard, C; Saluja, A; Saluja, M; Schnettler, E; Vogel, RI | 1 |
| Chen, S; Tai, H; Tong, X; Wang, J; Yang, F; Yang, Y; Yiqin, O | 1 |
| Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J | 1 |
| Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B | 1 |
| Mannel, RS; Moore, KN; Slaughter, KN | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Chang, MC; Chen, CA; Cheng, WF; Chiang, YC; Hsieh, CY; Kuo, KT; Lin, HP; Lu, TP | 1 |
| Bruixola, G; Caballero, J; De La Cueva, H; Díaz, R; Domingo, S; Palomar, L; Santaballa, A | 1 |
| Bonneau, C; Castela, M; Cortez, A; Daraï, E; Geyl, C; Lis, R; Rouzier, R; Touboul, C | 1 |
| Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D | 1 |
| Borani, N; Karalök, MA; Keskin, HL; Köse, MF; Özgül, N; Tulunay, HG; Turan, AT; Üreyen, I | 1 |
| Chang, CH; Chen, CC; Chiu, WT; Chou, CY; Hsu, KF; Huang, SC; Huang, YF; Tsai, HY | 1 |
| Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC | 1 |
| Jansaka, N; Suprasert, P | 1 |
| Barbolina, MV; Choi, J; Gurler, H; Kajdacsy-Balla, AA; Yu, Y | 1 |
| Gaikwad, SM; Ray, P; Sakpal, A; Singh, RK; Thakur, B | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Armstrong, DK; Chan, JK; Herzog, T; Java, JJ; Markman, M; Monk, BJ; Salani, R; Tewari, D | 1 |
| Amiji, MM; Duan, Z; Feng, Y; Foster, R; Gao, Y; Hornicek, FJ; Mankin, HJ; Shen, JK; Yang, X | 1 |
| Amler, LC; Bais, C; Choi, Y; Firestein, R; Fu, L; Fuentes, E; Guan, Y; Huw, LY; Lackner, MR; Lu, S; Rabe, C; Ryner, L; Wang, Y; Xiao, Y | 1 |
| Katsumata, N | 2 |
| Fukuda, T; Hashiguchi, Y; Ichimura, T; Imai, K; Sumi, T; Teramae, M; Yamauchi, M; Yasui, T | 1 |
| Li, PL; Xu, A; Zhang, LY; Zhang, XC | 1 |
| Dandapani, M; Eng, KH; Goldberg, GL; Horwitz, SB; Odunsi, K; Odunsi-Akanji, O; Seagle, BL; Shahabi, S; Yang, CP | 1 |
| Ozbasar, D; Sakarya, DK; Yetimalar, MH | 1 |
| Cohen, JG; Li, AJ; Tran, AQ | 1 |
| Baba, T; Ishikawa, M; Kanato, K; Nakamura, K; Satoh, T; Shibata, T; Takano, M; Tsuda, H; Ushijima, K; Yaegashi, N; Yoshikawa, H | 1 |
| Anuradha, S; Brand, AH; Donovan, PJ; Friedlander, M; Goh, J; Jordan, SJ; Oehler, MK; Quinn, M; Steer, C; Webb, PM | 1 |
| Chang, TH; Chen, CC; Chou, CY; Huang, YF; Wu, YH | 1 |
| Cheng, X; Li, X; Lu, W; Mao, Y; Pan, Q; Wan, X; Xie, X | 1 |
| Koo, YJ; Lim, KT | 1 |
| Duk, MJ; Pasker-de Jong, PC; Schreuder, HW; van Vliet, MM | 1 |
| Cheng, L; Guo, Y; Hu, L; Lv, QL; Qin, CZ; Wu, NY; Zhou, HH | 1 |
| Bandera, EV; Kushi, LH; Lee, VS; Powell, CB; Rodriguez-Rodriguez, L | 2 |
| Bian, C; Li, L; Yao, K; Yi, T; Zhao, X | 1 |
| Kumar, L; Patel, S; Singh, N | 1 |
| Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H | 1 |
| Shi, C; Shuang, T; Wang, D; Wang, M; Zhou, Y | 1 |
| Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Do, IG; Hong, JE; Jeon, HK; Kim, BG; Kim, MK; Kim, TJ; Kim, WY; Lee, JW; Lee, SH; Lee, YY; Ryu, JY; Yoon, G | 1 |
| Bae, T; Choi, JW; Eum, KH; Kim, S; Lee, JW; Weon, KY | 1 |
| Chang, CF; Chang, MC; Chen, CA; Chen, TC; Cheng, WF; Chiang, YC; Fu, CF; Hsieh, SF; Lin, HW | 1 |
| Bouchard-Fortier, G; Covens, A; Ferguson, SE; Gien, LT; Kupets, R; Pasetka, M; Pulman, K; Rosen, B; Vicus, D; Vyarvelska, I | 1 |
| Qiang, WA; Tan, W; Wang, SP; Wang, YT; Zhong, ZF | 1 |
| Ge, G; Niu, L; Ren, Y; Yan, Y; Zhang, W; Zou, Y | 1 |
| Kim, JH; Lee, EJ; Lee, TJ; Nguyen, TM; Park, J; Park, MS; Shin, IW | 1 |
| Bae, DS; Byeon, Y; Cho, SK; Cho, YJ; Han, HD; Jeon, HN; Kim, BG; Kim, HS; Lee, JW; Lopez-Berestein, G; Park, YM; Shin, BC; Sood, AK | 1 |
| Eisenmann, KM; Khaing, M; Pettee, KM; Rubinic, K; Ziske, MA | 1 |
| Chiantera, V; Cosentino, F; Costantini, B; Fagotti, A; Fanfani, F; Ferrandina, G; Gallotta, V; Gueli Alletti, S; Margariti, PA; Scambia, G; Tortorella, L; Vizzielli, G | 1 |
| Ezendam, NP; Frielink, LM; Pijlman, BM; Pijnenborg, JM | 1 |
| Chang Chien, CC; Fu, HC; Huang, CC; Lin, H; Liu, JM; Liu, SC; Ma, YY; Ou, YC; Tsai, CC | 1 |
| Alvarez, RD; Becker, DA; Bevis, KS; Boone, JD; Gilbert, AL; Huh, WK; Leath, CA; Straughn, JM; Thomas, ED | 1 |
| Bookman, MA | 1 |
| Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS | 1 |
| Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y | 1 |
| Benedetto, C; Canuto, EM; Fishbein, L; Jean, S; Katsaros, D; Li, J; Maxwell, KN; McLane, MW; Mitra, N; Nathanson, KL; Tanyi, JL; Wubbenhorst, B; Zhang, L | 1 |
| Amadio, G; Di Stefano, MG; Fagotti, A; Ferandina, G; Paris, I; Petrillo, M; Salutari, V; Scambia, G | 1 |
| Bayar, A; Bereder, JM; Ferron, G; Glehen, O; Gouy, S; Le Deley, MC; Marchal, F; Morice, P; Pomel, C; Quenet, F | 1 |
| Chang, CL; Chen, JR; Chen, TC; Chien, HJ; Huang, CY; Wang, KL; Weng, CS; Yang, YC | 1 |
| Arévalo-Pérez, J; Barceló, F; Cascales-Campos, P; Gil, E; Gil, J; López-López, V; Nieto, A; Parrilla, P | 1 |
| Liu, CC; Lu, Y; Tang, H; Wang, H; Zhu, J | 1 |
| Hiramatsu, Y; Masuyama, H; Nakamura, K; Nobumoto, E | 1 |
| Otsuka, I; Shoji, K | 1 |
| Chi, DS; Gardner, GJ; Iasonos, A; Kelly, A; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Sonoda, Y; Zhou, Q; Zivanovic, O | 1 |
| Choi, KU; Do, KH; Kim, J; Kim, KH; Moon, Y; Park, SH | 1 |
| Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL | 1 |
| Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z | 1 |
| Bottoni, C; Costantini, B; Fagotti, A; Gallotta, V; Gueli Alletti, S; Nardelli, F; Petrillo, M; Quagliozzi, L; Scambia, G; Vizzielli, G | 1 |
| Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R | 1 |
| Ataseven, B; du Bois, A; Harter, P; Heitz, F; Hengsbach, A; Kurzeder, C; Prader, S; Schneider, S; Sporkmann, M; Traut, A | 1 |
| Artioli, G; Baldoni, A; Bergamini, A; Breda, E; Cannella, L; Cecere, SC; Colombo, N; Daniele, G; Ferrandina, G; Floriani, I; Greggi, S; Lo Re, G; Lorusso, D; Maltese, G; Nicoletto, MO; Perrone, F; Piccirillo, MC; Pignata, S; Raspagliesi, F; Salutari, V; Scambia, G; Signoriello, S; Tognon, G | 1 |
| Kang, SB; Kim, YM; Kim, YT; Lee, SW | 1 |
| Bae, DS; Cho, WC; Cho, YJ; Choi, CH; Choi, JJ; Choi, YL; Heo, EJ; Hong, JE; Jeon, HK; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Oh, DY; Park, WY; Song, SY | 1 |
| Seagle, BL; Shahabi, S | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Cartledge, D; Godwin, AK; Kouadio, A; Zhang, H | 1 |
| Berkowitz, RS; Gao, Z; Garner, EI; Litkouhi, B; McClane, B; Mok, SC; Welch, WR; Xu, X; Zeng, Q | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Bassett, R; Coleman, RL; Dos Reis, R; Harrell, R; Milam, MR; Ramirez, PT; Tao, X | 1 |
| Chicharoen, S; ImAim, C; Liabsuetrakul, T; Reungrairatanaroj, P | 1 |
| Aoki, D; Arao, T; Chiyoda, T; Kataoka, F; Nishimura, S; Nishio, K; Nomura, H; Susumu, N; Tsuda, H | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Rheaume, PS; Richardson, DL; Salani, R | 1 |
| Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI | 1 |
| Faught, W; Fung, MF; Hopkins, L; Jolicoeur, L; Latifah, H; Le, T; Weberpals, J | 1 |
| Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE | 1 |
| Atkinson, MA; Ferguson, SE; Helpman, L; Le, L; Mackay, H; Mackean, M; Rana, A; Rogerson, A | 1 |
| Brady, MF; Cohn, DE; Degeest, K; Hanjani, P; Hiura, M; Kohn, EC; Lee, R; Mannel, RS; Michael, H; Monk, BJ | 1 |
| Cui, H; Kong, L; Li, X; Wang, J; Wang, S; Wei, L; Xu, Q; Zhao, Y | 1 |
| Canuto, EM; Katsaros, D; Lu, L; Rutherford, T; Scarampi, L; Schwartz, P; Yu, H | 1 |
| Fauci, JM; Frederick, PJ; Kilgore, LC; Schneider, KE; Straughn, JM; Subramaniam, A; Whitworth, JM; Zhang, B | 1 |
| Farris, C; Krivak, TC; Lesnock, JL; Markman, M; Smith, KJ | 1 |
| Armstrong, DK; Chernofsky, MR; Farley, JH; Hamilton, CA; Krivak, TC; Markman, M; Maxwell, GL; Miller, A; Miller, C; Ozols, RF; Rose, GS; Stany, MP | 1 |
| Catot, S; Cervantes, A; Chiva, L; de Juan, A; Del Campo, JM; García, Y; García-Donas, J; González-Martín, A; Martínez, S; Oaknin, A; Ponce, J; Poveda, A; Redondo, A; Roda, D | 1 |
| Antsaklis, A; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Karadimou, A; Rodolakis, A; Sotiropoulou, M; Soupos, N; Thomakos, N; Zagouri, F | 1 |
| Han, MH; Hwang, JH; Kang, S; Kim, JH; Kong, SY; Lim, MC; Park, SY; Seo, SS; Yoo, CW; Yoo, HJ | 1 |
| Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Antsaklis, A; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Sakellariou, K; Sotiropoulou, M; Thomakos, N; Trachana, P; Vlahos, G; Zagouri, F | 1 |
| Aghajanian, CA; Bell-McGuinn, KM; Gerst, SR; Grabon, DM; Hensley, ML; Iasonos, A; Konner, JA; Pezzulli, SD; Sabbatini, PJ; Spriggs, DR; Tew, WP; Thaler, H | 1 |
| Brennan, D; Fitzpatrick, P; Furlong, F; Gallagher, M; Maguire, A; Martin, C; McCann, A; McGettigan, P; McGoldrick, A; McGrogan, B; O'Grady, A; O'Leary, J; O'Toole, S; Phelan, S; Prencipe, M; Sheils, O; W Kay, E | 1 |
| Beriwal, S; Edwards, RP; Krivak, TC; Lesnock, JL; McBee, WC; Richard, SD; Skaznik-Wikiel, ME; Zorn, KK | 1 |
| Aoki, D; Jobo, T; Katsumata, N; Kumagai, S; Michimae, H; Ochiai, K; Shoji, T; Sugiyama, T; Terauchi, F; Yasuda, M | 1 |
| Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R | 1 |
| Birrer, MJ; Boente, M; Bookman, MA; Brady, MF; Burger, RA; Fleming, GF; Fowler, J; Greer, BE; Homesley, HD; Huang, H; Liang, SX; Mannel, RS; Monk, BJ | 1 |
| Beale, P; Carey, MS; Cervantes, A; Collinson, F; du Bois, A; Essapen, S; Gourley, C; Kimmig, R; Kristensen, G; Kurzeder, C; Ledermann, JA; Leminen, A; Lortholary, A; Mirza, MR; Oza, AM; Parmar, MK; Perren, TJ; Pfisterer, J; Plante, M; Pujade-Lauraine, E; Qian, W; Sehouli, J; Selle, F; Stähle, A; Stark, D; Swart, AM | 1 |
| Armstrong, DK; Birrer, M; Bookman, MA; Darcy, KM; Deloia, J; Dhir, R; Krivak, TC; Muggia, F; Niedernhofer, LJ; Rubatt, JM; Tian, C | 1 |
| Jeon, HW; Jeon, YT; Kim, H; Kim, K; Kim, YB; No, JH | 1 |
| Hellström, I; Hellström, KE; Wei, H | 1 |
| Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S | 1 |
| Li, XP; Wang, JL; Wang, SJ; Wei, LH; Xu, QY; Zhao, Y | 1 |
| Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K | 1 |
| Azodi, M; Glasgow, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Yu, H | 1 |
| Bassi, A; Belotti, D; Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Oliva, P; Pesenti, E; Scanziani, E | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Chen, Y; Liu, N; Zhao, J; Zhou, C | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Lichtman, SM; Power, DG; Teo, MY; Tew, WP | 1 |
| Lowe, MP; Schwartzberg, LS; Stepanski, EJ; Tillmanns, TD; Walker, MS | 1 |
| Li, H; Li, J; Liu, G; Yin, D; Zhang, J; Zhang, S; Zhang, W; Zhao, J | 1 |
| Abdulkadir, L; Amant, F; Berteloot, P; Cadron, I; Despierre, E; Leunen, K; Neven, P; Vergote, I | 1 |
| Aneke, H; Curtin, NJ; Edmondson, RJ; Elattar, A; Maxwell, P; McCluggage, WG; Mukhopadhyay, A; Plummer, ER; Quinn, JE; Soohoo, S; Uzir, B | 1 |
| Li, GT | 1 |
| Auranen, A; Carpén, O; Grénman, S; Hynninen, J; Lavonius, M; Oksa, S | 1 |
| Butler-Manuel, S; Essapen, S; Larbi, E; Madhuri, K; Michael, A; Tailor, A | 1 |
| Liu, P; Mao, HL; Pang, Y; Wang, Y; Yang, F; Zhang, X; Zheng, J | 1 |
| Duan, Z; Hu, P; Yue, Y; Zhou, X | 1 |
| Bagnato, A; Baumann, K; Cognetti, F; Colombo, N; Harter, P; Mari, E; McIntosh, S; Nathan, F; Pemberton, K; Savarese, A; Scambia, G; Sehouli, J; Sorio, R; Wimberger, P | 1 |
| Cao, Y; Han, Y; Huang, H; Qu, L; Shou, C; Xiao, Z; Zhang, W | 1 |
| Chang, MC; Chen, CA; Chen, PJ; Cheng, WF; Chiang, YC; Hsieh, CY; Wu, MM | 1 |
| Bickel, LE; Connolly, DC; Do, TV; Ecsedy, JA; Godwin, AK; Golemis, EA; Howe, C; Hua, X; Klein-Szanto, AJ; Litwin, S; Maglaty, M; O'Brien, SW; Pathak, HB; Schilder, RJ; Xiao, F | 1 |
| Asai, M; Asai, N; Enomoto, A; Horio, M; Kato, T; Kikkawa, F; Mii, S; Murakumo, Y; Shibata, K; Takahashi, M | 1 |
| Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L | 1 |
| Chen, L; Gong, L; Liang, L; Lin, F; Liu, N; Pan, S; Yan, X; Zhang, Q; Zhao, H; Zheng, F | 1 |
33 review(s) available for paclitaxel and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Feasibility Studies; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2022 |
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Topics: Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2022 |
Optimizing regional chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2022 |
Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum-Paclitaxel Chemotherapy: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models | 2023 |
Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Ovarian Neoplasms; Paclitaxel | 2022 |
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis | 2023 |
Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2023 |
Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Immunotherapy; Ovarian Neoplasms; Paclitaxel | 2023 |
Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Mortality; Neoadjuvant Therapy; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Perioperative Period; Postoperative Complications; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tumor Burden | 2020 |
HIPEC in advanced epithelial ovarian cancer: why is there controversy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2020 |
Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Precision Medicine | 2021 |
Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Prognosis; Tumor Microenvironment | 2018 |
Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2017 |
Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2017 |
Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Quality of Life; Survival Rate; Treatment Outcome | 2018 |
Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel | 2019 |
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Mutation; Ovarian Neoplasms; Paclitaxel | 2019 |
[Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CN
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; France; Humans; Indoles; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Phthalazines; Piperazines; Societies, Medical | 2019 |
[Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian can
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Societies, Medical | 2019 |
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic | 2013 |
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2013 |
Ovarian pulmonary-type small cell carcinoma: case report and review of the literature.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carrier Proteins; Female; Humans; Keratins; Lung; Middle Aged; Neoplasms, Glandular and Epithelial; Neural Cell Adhesion Molecules; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed; Ubiquitin-Protein Ligases | 2013 |
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic | 2013 |
Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients.
Topics: Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Standard of Care; Treatment Outcome | 2013 |
Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2014 |
First-line and maintenance therapy for ovarian cancer: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors | 2014 |
Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2014 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Dose-dense approaches to ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2015 |
Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Fertility Preservation; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2015 |
Optimal primary therapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality Improvement | 2016 |
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2011 |
89 trial(s) available for paclitaxel and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intercellular Signaling Peptides and Proteins; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins | 2021 |
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Somatomedins | 2021 |
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People | 2022 |
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Topics: Adult; Aged; Aged, 80 and over; Allelic Imbalance; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Hereditary Breast and Ovarian Cancer Syndrome; Humans; Induction Chemotherapy; Loss of Heterozygosity; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Proportional Hazards Models; Recombinational DNA Repair; Young Adult | 2022 |
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Hereditary Breast and Ovarian Cancer Syndrome; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Young Adult | 2022 |
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dendritic Cells; Female; Humans; Immunotherapy; Mice; Middle Aged; Paclitaxel; Young Adult | 2022 |
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Belgium; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Luxembourg; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2022 |
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2022 |
DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2022 |
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2022 |
Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis; Quality of Life; Receptors, CXCR4 | 2022 |
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2022 |
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis | 2022 |
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2022 |
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Duration of Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2023 |
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2023 |
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2023 |
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence | 2023 |
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2023 |
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Quality of Life | 2023 |
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Female; Humans; Intercellular Signaling Peptides and Proteins; Ovarian Neoplasms; Paclitaxel | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bioaccumulation; Blood Glucose; Brain; Brassica napus; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Catalysis; Child; China; Chlorides; Chlorine; Chromium; Chronic Disease; Cohort Studies; Copper; Corrosion; COVID-19; Creatinine; Dermatitis; Diabetes Mellitus; Diazepam; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dyspnea; Electron Spin Resonance Spectroscopy; Environmental Monitoring; Escherichia coli; Escherichia coli Infections; Esophageal Neoplasms; Esophagogastric Junction; Estradiol; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Fishes; Food Chain; gamma-Aminobutyric Acid; Genomics; Halogenation; HEK293 Cells; Hemolysis; Heterocyclic Compounds; Hospitalization; Humans; Hydrogen Peroxide; Hyperglycemia; Introns; Iron; Kidney; Kinetics; Laboratories; Limit of Detection; Lipopolysaccharides; Liver Neoplasms; Magnesium; Male; Mammals; Materials Testing; Mercury; Metal-Organic Frameworks; Methylmercury Compounds; Mice; Microscopy, Electron, Scanning; Mifepristone; Minerals; Molecular Weight; Mutation; Nanoparticles; Neuroprotection; NF-kappa B; Nitrates; Nitrogen; NLR Family, Pyrin Domain-Containing 3 Protein; Orthopedics; Ovarian Neoplasms; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Oxygen; Oxygen Consumption; Paclitaxel; Phenols; Progesterone; Prospective Studies; Proteins; Protons; Pulmonary Disease, Chronic Obstructive; Ramucirumab; Rats; Receptor, ErbB-2; Respiratory Function Tests; Retrospective Studies; Saliva; SARS-CoV-2; Seeds; Sesbania; Shock, Septic; Silicon Dioxide; Sleep; Soil; Specimen Handling; Spectroscopy, Mossbauer; Spin Labels; Staphylococcus aureus; Stomach Neoplasms; Streptococcus mutans; Thiamine; Toll-Like Receptor 2; Toll-Like Receptor 4; Trastuzumab; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Water; Water Pollutants, Chemical; Water Purification; Xeroderma Pigmentosum; Zebrafish | 2023 |
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2023 |
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan | 2019 |
Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Metformin; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Progression-Free Survival; Prospective Studies; Signal Transduction | 2019 |
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival | 2020 |
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2020 |
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Interleukin-6; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Survival Analysis | 2020 |
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Metformin; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2020 |
Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2020 |
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Progression-Free Survival; Randomized Controlled Trials as Topic | 2020 |
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2021 |
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Double-Blind Method; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Young Adult | 2021 |
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Progression-Free Survival | 2021 |
Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2021 |
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Data Interpretation, Statistical; Female; Humans; Neoplasm Grading; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Reproducibility of Results; Research Design; Response Evaluation Criteria in Solid Tumors; Survival Analysis | 2021 |
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Quinolines | 2021 |
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival | 2018 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2018 |
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult | 2018 |
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Young Adult | 2018 |
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2018 |
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Young Adult | 2019 |
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyridines | 2019 |
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Young Adult | 2019 |
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Humans; Internationality; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Progression-Free Survival; Quality of Life; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult | 2019 |
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate | 2019 |
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Carboplatin; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulin Fc Fragments; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Wnt Signaling Pathway | 2019 |
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
Topics: Adrenergic beta-Antagonists; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytokines; Feasibility Studies; Female; Gene Expression; Humans; Leukocytes; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Propranolol; Prospective Studies; Quality of Life | 2019 |
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Ovarian Epithelial; Chromatography, High Pressure Liquid; Cisplatin; Drug Administration Schedule; Drug Interactions; Female; Half-Life; Humans; Infusions, Intravenous; Liver; Metabolic Clearance Rate; Models, Biological; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Saponins; Triterpenes | 2014 |
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method | 2013 |
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models | 2013 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2014 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Edema; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Withholding Treatment | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2014 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Image; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Length of Stay; Middle Aged; Neoplasms, Glandular and Epithelial; Operative Time; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Quality of Life; Young Adult | 2016 |
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan | 2016 |
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Maintenance Chemotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2016 |
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult | 2017 |
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2017 |
An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Micelles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Republic of Korea | 2017 |
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome | 2011 |
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate | 2011 |
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Outpatients; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Spain; Treatment Outcome | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 2011 |
Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Hemoglobins; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2011 |
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis; Young Adult | 2011 |
A phase 3 trial of bevacizumab in ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis | 2011 |
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult | 2012 |
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; DNA Breaks, Double-Stranded; Enzyme Inhibitors; Female; Homologous Recombination; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors | 2012 |
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2013 |
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-O
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Placebos; Pyrrolidines; Young Adult | 2013 |
276 other study(ies) available for paclitaxel and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Glutathione Transferase; Humans; Middle Aged; Paclitaxel; Up-Regulation | 2021 |
IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Integrin alpha6; Mice; Neoplasm Metastasis; Paclitaxel; Platinum; Receptor, IGF Type 1; S100 Calcium-Binding Protein A4; Signal Transduction | 2022 |
Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Cisplatin; Endometriosis; Female; Humans; Laparotomy; Middle Aged; Ovarian Cysts; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2021 |
Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 6; Female; Humans; MicroRNAs; Ovarian Neoplasms; Paclitaxel | 2021 |
A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ibogaine; Molecular Structure; Ovarian Neoplasms; Paclitaxel | 2022 |
Ovarian high-grade serous carcinoma with elevated β-human chorionic gonadotropin: A case report.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Chorionic Gonadotropin; Chorionic Gonadotropin, beta Subunit, Human; Cytoreduction Surgical Procedures; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pregnancy | 2021 |
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy-Related Cognitive Impairment; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fatigue; Female; Humans; Long Term Adverse Effects; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Sleep Initiation and Maintenance Disorders | 2022 |
Arborinine suppresses ovarian cancer development through inhibition of LSD1.
Topics: Acridines; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; China; Cisplatin; Epithelial-Mesenchymal Transition; Female; Histone Demethylases; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Ovary; Paclitaxel; Xenograft Model Antitumor Assays | 2022 |
Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Humans; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Quality of Life; Tertiary Care Centers | 2022 |
The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carbamoyl-Phosphate Synthase (Ammonia); Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; LIM Domain Proteins; Mice; Mice, Nude; Middle Aged; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Taxoids; Transcription Factors | 2021 |
Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors | 2022 |
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Hypertension; Ovarian Neoplasms; Paclitaxel; Proteinuria | 2022 |
Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Paclitaxel; Systematic Reviews as Topic | 2022 |
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel | 2022 |
High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Female; Humans; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tumor Microenvironment | 2022 |
Navicixizumab plus Paclitaxel Shows Clinical Benefit in Platinum-Resistant Ovarian Cancer.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2022 |
The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Interferon-gamma; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Phosphoproteins | 2022 |
Linking unfolded protein response to ovarian cancer cell fusion.
Topics: Carcinoma, Ovarian Epithelial; Cell Fusion; Cell Line, Tumor; Female; Humans; Hypoxia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyploidy; Unfolded Protein Response | 2022 |
CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Topics: Carcinoma; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Glucosephosphate Dehydrogenase; Humans; Ovarian Neoplasms; Paclitaxel; STAT3 Transcription Factor | 2022 |
Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Quality of Life; Retrospective Studies | 2022 |
The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Survival; Cisplatin; Female; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hyaluronoglucosaminidase; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Messenger; RNA, Small Interfering | 2022 |
Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Delivery Systems; Estrone; Female; Humans; Liposomes; Mice; Mice, Inbred ICR; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Tissue Distribution | 2022 |
Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods.
Topics: Carcinoma, Ovarian Epithelial; Dual Specificity Phosphatase 1; Female; Humans; MAP Kinase Signaling System; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Tumor Microenvironment | 2022 |
Changes in subcellular localization of Lysyl-tRNA synthetase and the 67-kDa laminin receptor in epithelial ovarian cancer metastases.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Female; Humans; Lysine-tRNA Ligase; Mice; Ovarian Neoplasms; Paclitaxel; Receptors, Laminin; Ribosomal Proteins | 2022 |
Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glutamine; Humans; Mechanistic Target of Rapamycin Complex 1; Ovarian Neoplasms; Paclitaxel; Ribosomal Protein S6 Kinases; Signal Transduction | 2022 |
Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Complex Mixtures; Cyclin B1; Cyclin-Dependent Kinase 4; Cyclooctanes; Cysteine; Dioxoles; Eosine Yellowish-(YS); Female; Humans; Lignans; Mice; Ovarian Neoplasms; Oxidative Stress; Paclitaxel; Reactive Oxygen Species | 2022 |
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Topics: Antineoplastic Agents; BRCA1 Protein; Carcinoma, Ovarian Epithelial; CDC2 Protein Kinase; Female; Homologous Recombination; Humans; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Duration of Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2023 |
[Ⅰ. Dose-Dense Chemotherapy in Ovarian Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2023 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |
Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2023 |
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2023 |
CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Topics: Animals; Antigens, CD; ATP-Binding Cassette Transporters; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; GPI-Linked Proteins; Humans; Mice; Neoplasm Proteins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Receptor, Notch1; STAT3 Transcription Factor | 2023 |
[A Case of Myelodysplastic Syndrome Developed during Chemotherapy for Postoperative Recurrent Ovarian Cancer That Progressed to Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2023 |
Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer.
Topics: CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Liposomes; Matrix Metalloproteinase 2; Matrix Metalloproteinase 7; Matrix Metalloproteinase 9; Ovarian Neoplasms; Paclitaxel | 2023 |
The role of inflammatory factors and T-cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Interferon-gamma; Interleukin-6; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 2023 |
Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2023 |
The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Folic Acid; Humans; Nanoparticles; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations | 2023 |
Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Ribosomes | 2019 |
Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cell Movement; Cell Proliferation; Connective Tissue Growth Factor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Galectin 1; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding; Signal Transduction | 2019 |
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2020 |
Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Esomeprazole; Female; Humans; Ovarian Neoplasms; Paclitaxel; Proton Pump Inhibitors; Transcription Factors; Tumor Microenvironment; Vacuolar Proton-Translocating ATPases; YAP-Signaling Proteins | 2019 |
Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Topics: Adult; Aged; Animals; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2020 |
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Rate | 2020 |
Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Gene Expression; Gene Knockdown Techniques; Humans; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; Paclitaxel; Receptor, Fibroblast Growth Factor, Type 1; Sialyltransferases; Signal Transduction | 2020 |
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Italy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Carcinoma, Ovarian Epithelial; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells.
Topics: Animals; Antihypertensive Agents; Apoptosis; Calcium Channel Blockers; Calcium Channels; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dihydropyridines; Drug Repositioning; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Nitrobenzenes; Ovarian Neoplasms; Paclitaxel; Piperazines; Signal Transduction; Tumor Microenvironment | 2020 |
A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Ovarian Neoplasms; Paclitaxel; Verteporfin | 2020 |
Dose-dense chemotherapy: A possible high cost-effectiveness treatment for ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2020 |
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Organoids; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Precision Medicine | 2020 |
Efficacy of weekly paclitaxel for the treatment of advanced ovarian cancer: A protocol for systematic review and meta-analysis.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Paclitaxel; Systematic Reviews as Topic; Treatment Outcome | 2020 |
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hyperthermic Intraperitoneal Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors | 2021 |
The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Progression-Free Survival | 2020 |
Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzoates; Bridged Bicyclo Compounds, Heterocyclic; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Immediate-Early Proteins; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; RNA, Small Interfering; Vacuolar Proton-Translocating ATPases | 2020 |
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment | 2020 |
Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Gene Frequency; Genotype; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Progression-Free Survival; Proto-Oncogene Proteins c-mdm2; Treatment Outcome; Tumor Suppressor Protein p53 | 2020 |
Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; DNA Copy Number Variations; Drug Administration Schedule; Drug Resistance, Neoplasm; Exome Sequencing; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Tubulin Modulators | 2020 |
The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Movement; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured | 2020 |
Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Paclitaxel | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Hyperthermic Intraperitoneal Chemotherapy; Laparotomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2021 |
Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points".
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2021 |
Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinases, Secreted; Ovarian Neoplasms; Paclitaxel; RNA, Long Noncoding; Transfection | 2021 |
Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; RNA, Long Noncoding; Survival Analysis; Transfection; Up-Regulation | 2020 |
GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Glutathione S-Transferase pi; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Progression-Free Survival; Young Adult | 2021 |
Changes in left ventricular function induced by carboplatin combined with paclitaxel in patients with ovarian cancer identified using three-dimensional spot tracking imaging technology.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Echocardiography; Echocardiography, Three-Dimensional; Female; Heart; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; ROC Curve; Stroke Volume; Ventricular Function, Left | 2021 |
Ultrasound-Mediated Long-Circulating Nanopolymer Delivery of Therapeutic siRNA and Antisense MicroRNAs Leads to Enhanced Paclitaxel Sensitivity in Epithelial Ovarian Cancer Chemotherapy.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering | 2020 |
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase I as Topic; Female; Genes, BRCA1; Genes, BRCA2; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2021 |
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Rad51 Recombinase | 2021 |
Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Datasets as Topic; Down-Regulation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; MicroRNAs; Middle Aged; Ovarian Neoplasms; Ovariectomy; Ovary; Paclitaxel; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2021 |
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Topics: Adipocytes; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cytoreduction Surgical Procedures; Epithelial-Mesenchymal Transition; Fatty Acids; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplastic Stem Cells; Ovarian Neoplasms; Oxidation-Reduction; Paclitaxel; Transcriptome | 2021 |
Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chlorides; Drug Synergism; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Tropomyosin; Up-Regulation; Vinorelbine | 2021 |
MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Topics: 3' Untranslated Regions; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2022 |
Phosphorylation of Cofilin-1 Enhances Paclitaxel Resistance of Epithelial Ovarian Cancer Cells by Inhibiting Apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cofilin 1; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation | 2021 |
Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2021 |
Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Guideline Adherence; Gynecologic Surgical Procedures; Gynecology; Humans; Medical Oncology; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Surgical Oncology; Survival Analysis; Treatment Outcome | 2017 |
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Catheters, Indwelling; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Randomized Controlled Trials as Topic; Tumor Microenvironment | 2017 |
Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; New Zealand; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Prognosis; Retrospective Studies; Treatment Outcome | 2017 |
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Female; Forkhead Box Protein O1; Forkhead Box Protein O3; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Young Adult | 2017 |
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2017 |
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein M1; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Thiostrepton | 2017 |
The anti-cancer effects of itraconazole in epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Proliferation; Disease Models, Animal; Drug Synergism; Endothelial Cells; Female; Heterografts; Itraconazole; Mice; Neoplasm Transplantation; Paclitaxel; Treatment Outcome | 2017 |
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2017 |
Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glucosides; Glycolysis; Herbal Medicine; Humans; Hyaluronan Receptors; Hydrolyzable Tannins; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proteomics; Signal Transduction; STAT3 Transcription Factor | 2017 |
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Topics: Apoptosis; beta Karyopherins; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Ivermectin; Loss of Function Mutation; Neoplasms, Glandular and Epithelial; Oncogenes; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering | 2017 |
iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Cells, Circulating; Ovarian Neoplasms; Paclitaxel | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies | 2017 |
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Hypoxia; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; G2 Phase Cell Cycle Checkpoints; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2018 |
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Genome-Wide Association Study; Genome, Human; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; Polymorphism, Single Nucleotide | 2018 |
Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Endometriosis; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
HIPEC improves survival in stage III epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Metformin; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Survival Rate | 2018 |
Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Young Adult | 2018 |
Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Paclitaxel; Primary Cell Culture; Survivin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2018 |
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2016 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Protein Serine-Threonine Kinases; Transfection; Up-Regulation | 2018 |
Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polycomb Repressive Complex 1; Prognosis; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2018 |
CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Gene Silencing; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; RNA, Small Interfering | 2018 |
Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; B7-H1 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Drug Combinations; Drug Synergism; Female; Humans; Immunotherapy; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2018 |
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Neoplasm; Tubulin Modulators; Xenograft Model Antitumor Assays | 2018 |
Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Propensity Score; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety | 2018 |
miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Topics: Adult; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclin D1; Drug Resistance, Neoplasm; Epigenesis, Genetic; F-Box Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Mice; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Signal Transduction; Tumor Burden; Vimentin; Xenograft Model Antitumor Assays; Zonula Occludens-1 Protein | 2018 |
LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1.
Topics: Adult; Aged; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Middle Aged; Multidrug Resistance-Associated Proteins; Paclitaxel; RNA, Long Noncoding | 2018 |
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan | 2019 |
SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Paclitaxel; Rats; Rats, Inbred F344; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Smad3 Protein; Survival Analysis; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate | 2018 |
The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies | 2019 |
Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2019 |
A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2019 |
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Time Factors; Treatment Outcome | 2019 |
Ovarian Mucinous Carcinoma with Mural Carcinosarcomatous Components in a Prepubertal Girl.
Topics: Adenocarcinoma, Mucinous; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Ovarian Neoplasms; Paclitaxel | 2019 |
Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Collagen Type XI; Cyclohexanones; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Twist-Related Protein 1; Xenograft Model Antitumor Assays | 2019 |
Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Female; Fibronectins; Focal Adhesion Kinase 1; GTP-Binding Proteins; Humans; Integrin beta1; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Ovarian Neoplasms; Paclitaxel; Protein Binding; Protein Glutamine gamma Glutamyltransferase 2; Pyrimidines; Signal Transduction; Transglutaminases; Xenograft Model Antitumor Assays | 2019 |
A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis.
Topics: Adult; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Cisplatin; Cystadenocarcinoma, Mucinous; Female; Humans; Hysterectomy; Neoplasm Metastasis; Omentum; Ovarian Neoplasms; Paclitaxel; Pelvis; Salpingo-oophorectomy; Tomography, X-Ray Computed | 2019 |
Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2019 |
MicroRNA-128/homeobox B8 axis regulates ovarian cancer cell progression.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2019 |
Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Proliferation; Combined Modality Therapy; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Nude; MicroRNAs; Nanoparticles; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Cytoreduction Surgical Procedures; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors | 2019 |
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Guideline Adherence; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Practice Patterns, Physicians'; Registries | 2013 |
The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer.
Topics: Biomarkers, Pharmacological; Calcium-Binding Proteins; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Chromosomal Instability; Female; Genetic Association Studies; Humans; M Phase Cell Cycle Checkpoints; Mad2 Proteins; Microtubules; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nocodazole; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Repressor Proteins | 2013 |
Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Disease-Free Survival; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Tumor Cells, Cultured | 2013 |
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival; Treatment Outcome | 2013 |
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Lymphatic Metastasis; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2013 |
DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Gene Expression; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; tau Proteins; Treatment Outcome | 2013 |
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Coculture Techniques; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2014 |
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; RNA Interference | 2013 |
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models | 2013 |
The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Data Collection; Female; Gynecology; Humans; Medical Oncology; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2013 |
Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Robotics; Treatment Outcome | 2013 |
[Chemotherapy in epithelial ovarian cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2013 |
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-6; Janus Kinase 2; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, Colony-Stimulating Factor; Signal Transduction; STAT3 Transcription Factor | 2014 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Choline; Choline Kinase; Down-Regulation; Doxorubicin; Female; Humans; Lipid Metabolism; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Platinum; RNA Interference; Signal Transduction; Transcriptome | 2014 |
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2014 |
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Recurrence; Snail Family Transcription Factors; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Disease-Free Survival; Female; Humans; Leukocytosis; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Preoperative Period; Proportional Hazards Models; Retrospective Studies; Young Adult | 2014 |
Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cholinergic Antagonists; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lactones; Lymphocyte Antigen 96; Molecular Docking Simulation; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Protein Conformation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Toll-Like Receptor 4; Tumor Cells, Cultured | 2014 |
Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2014 |
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2014 |
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2014 |
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; tau Proteins; Treatment Outcome | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis.
Topics: Adolescent; Adult; Aged; Apoptosis Regulatory Proteins; Beclin-1; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Membrane Proteins; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Young Adult | 2014 |
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Topics: Adiposity; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Intra-Abdominal Fat; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Pilot Projects; Prognosis; Proportional Hazards Models; Retrospective Studies; Subcutaneous Fat; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Disease-Free Survival; Female; Health Care Costs; Humans; Middle Aged; Models, Economic; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Vascular Endothelial Growth Factor A | 2014 |
Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cytotoxins; Dose-Response Relationship, Drug; Drug Synergism; Female; Gonadotropin-Releasing Hormone; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH | 2014 |
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cohort Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Burden | 2014 |
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Immunohistochemistry; MicroRNAs; Middle Aged; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Prognosis; RNA, Small Interfering; Signal Transduction; Survival Analysis; Toll-Like Receptor 4 | 2014 |
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Epithelial Cell Adhesion Molecule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prognosis; Tissue Banks; Treatment Outcome | 2014 |
Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Synergism; Female; Flavonoids; Humans; In Situ Nick-End Labeling; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Xenograft Model Antitumor Assays | 2015 |
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Podophyllotoxin; Proteasome Endopeptidase Complex; Receptor, IGF Type 1 | 2014 |
Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Electric Impedance; Epoxy Compounds; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Organophosphates; Ovarian Neoplasms; Paclitaxel; Phenanthrenes; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Plasminogen Activator Inhibitor 1; Prognosis; Retrospective Studies; Survival Analysis | 2014 |
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2015 |
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Establishment of a New Ovarian Cancer Cell Line CA5171.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cisplatin; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phenotype; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Tumor Suppressor Protein p53 | 2015 |
Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2015 |
Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Hyaluronan Receptors; Interleukin-6; Interleukin-8; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2015 |
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models | 2015 |
Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Young Adult | 2014 |
FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Immunohistochemistry; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; RNA Interference; Survival Analysis; Thiostrepton; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Collagen Type I; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Immunohistochemistry; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Isoforms; RNA Interference; RNA, Small Interfering; tau Proteins | 2015 |
Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cisplatin; Female; Humans; Mice; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2015 |
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chi-Square Distribution; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fibroblasts; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transcriptome; Treatment Outcome; Tumor Microenvironment; Up-Regulation | 2015 |
Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate | 2015 |
Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering | 2015 |
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Epothilones; Female; Genes, p53; Humans; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin Modulators; Tumor Suppressor Protein p53 | 2015 |
Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2015 |
A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Fertility; Humans; Infertility, Female; Japan; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salpingostomy; Treatment Outcome | 2015 |
Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Time Factors | 2016 |
COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
Topics: Antineoplastic Agents; Binding Sites; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cisplatin; Collagen Type XI; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Profiling; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA Interference; RNA, Messenger; RNA, Small Interfering; Ubiquitination | 2015 |
Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclin G1; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Loci; Humans; Methylation; MicroRNAs; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA Interference; RNA, Messenger | 2015 |
Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Catheter Obstruction; Catheters, Indwelling; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Diarrhea; Disease-Free Survival; Female; Humans; Ileus; Infusions, Parenteral; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate; Vomiting; Withholding Treatment | 2015 |
Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cyclophosphamide; Cytoreduction Surgical Procedures; Delivery of Health Care; Disease-Free Survival; Female; Follow-Up Studies; Health Status; Hospitals, Teaching; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2015 |
Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Marrow; Carboplatin; Carcinoma, Ovarian Epithelial; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Leukocyte Count; Leukopenia; Middle Aged; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Paclitaxel; Paresthesia; Pharmacogenomic Variants; Prospective Studies | 2016 |
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; California; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Drug Dosage Calculations; Health Maintenance Organizations; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Obesity; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2016 |
Metformin and epithelial ovarian cancer therapeutics.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2015 |
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2015 |
Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Base Sequence; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Nucleic Acid | 2015 |
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Gene Knockdown Techniques; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Omeprazole; Ovarian Neoplasms; Paclitaxel; Proton Pump Inhibitors; RNA, Small Interfering; Transfection; Vacuolar Proton-Translocating ATPases; Xenograft Model Antitumor Assays | 2015 |
Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzazepines; Carcinoma, Ovarian Epithelial; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Indoles; Mice, Inbred C57BL; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
Topics: Adipokines; Adult; Aged; Analysis of Variance; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chitinase-3-Like Protein 1; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lectins; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2015 |
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Young Adult | 2016 |
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quinazolines | 2015 |
miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein | 2016 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Topics: Adenoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Tumor Stem Cell Assay | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore | 2015 |
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
Topics: Acyclic Monoterpenes; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Membrane Potential, Mitochondrial; Mice; Monoterpenes; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Formins; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Spheroids, Cellular; Thiones; Uracil | 2016 |
Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models | 2016 |
Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-myc; Survival Rate; tau Proteins; Tumor Suppressor Protein p53 | 2016 |
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome | 2016 |
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; DNA Copy Number Variations; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Sequence Analysis, DNA; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2016 |
Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Lymphocyte Count; Membrane Proteins; Middle Aged; Monocytes; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Paclitaxel; Platelet Count; Retrospective Studies; Treatment Outcome | 2016 |
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Ethnicity; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Racial Groups; Young Adult | 2016 |
Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2016 |
Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Humans; Ketoconazole; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phthalic Acids; Pregnane X Receptor; Pregnenolone; Receptors, Steroid; RNA, Small Interfering; Signal Transduction | 2016 |
Paraaortic node recurrence 25 years after removal of epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Remission Induction; Treatment Outcome | 2016 |
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2016 |
NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemokines; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorescent Antibody Technique; Growth Differentiation Factor 15; Humans; Immunohistochemistry; Inflammation; Kaplan-Meier Estimate; MAP Kinase Kinase Kinases; Microscopy, Confocal; Myeloid Differentiation Factor 88; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; NF-kappa B; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Signal Transduction; Smad4 Protein; Sulindac; Up-Regulation | 2016 |
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Laparoscopy; Laparotomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies | 2016 |
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Survival Rate; Time Factors | 2016 |
Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Germany; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Retrospective Studies; Severity of Illness Index; Survival Rate; Young Adult | 2017 |
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Topics: Adult; Animals; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Female; Genomic Instability; Heterografts; Humans; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2017 |
Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
Topics: Administration, Intravenous; Anemia; Antineoplastic Agents; Blood Transfusion; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Filgrastim; Hematologic Agents; Hospitalization; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2017 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Role of gamma-synuclein in microtubule regulation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cytoskeleton; Female; Fluorescent Antibody Technique; gamma-Synuclein; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured | 2011 |
C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cells, Cultured; Claudin-4; Clostridium perfringens; Enterotoxins; Epithelial Cells; Female; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Membrane Proteins; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; RNA, Messenger; Tight Junctions; Ubiquitin-Protein Ligase Complexes; Xenograft Model Antitumor Assays | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
Synergistic growth-inhibitory effects of fenretinide with either cisplatin or paclitaxel on human epithelial ovarian cancer cell line (SKOV-3).
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cisplatin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fenretinide; Growth Inhibitors; Humans; Inhibitory Concentration 50; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2004 |
Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cofilin 1; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Laparotomy; Microdissection; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2011 |
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2011 |
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan | 2011 |
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2011 |
Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Ovarian Epithelial; Complementary Therapies; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Surveys and Questionnaires; Survival Rate; Treatment Outcome; United Kingdom | 2011 |
The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies | 2011 |
MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2011 |
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2011 |
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Markov Chains; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis | 2011 |
Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Disease-Free Survival; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proteins; Serum; WAP Four-Disulfide Core Domain Protein 2 | 2012 |
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum | 2012 |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine | 2011 |
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Time Factors; Treatment Outcome | 2012 |
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium-Binding Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mad2 Proteins; MicroRNAs; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Proportional Hazards Models; Repressor Proteins; Retrospective Studies; Risk Assessment; Risk Factors; RNA Interference; Time Factors; Transfection; Treatment Outcome | 2012 |
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pennsylvania; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Female; Genotype; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; Young Adult | 2012 |
Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2012 |
Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cisplatin; Elafin; Female; Fluorouracil; Gene Knockdown Techniques; Gene Silencing; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transfection | 2012 |
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 2012 |
Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
Topics: Aged; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease Progression; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A | 2012 |
[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Repressor Proteins; RNA, Messenger; Tubulin | 2012 |
Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aptamers, Nucleotide; Artificial Gene Fusion; Base Sequence; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Molecular Sequence Data; Mucin-1; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Doublet chemotherapy in the elderly patient with ovarian cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Clinical Trials as Topic; Female; Geriatric Assessment; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microarray Analysis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction | 2012 |
The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2013 |
[Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Routes; Evidence-Based Medicine; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2013 |
Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasms, Glandular and Epithelial; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Skin; Survivin; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2013 |
A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Intestinal Perforation; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2012 |
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Blood Proteins; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Regulatory Networks; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Principal Component Analysis; ROC Curve; Taxoids; Transcriptome | 2012 |
Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Epigenomics; Female; Gene Silencing; Humans; Methylation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Small Interfering; Tumor Suppressor Proteins | 2013 |
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Azepines; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Female; Humans; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays | 2014 |
Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering; Treatment Failure; Xenograft Model Antitumor Assays | 2012 |
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate | 2013 |
Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; RNA, Small Interfering; Survivin; Young Adult | 2013 |